

**“COMPARATIVE EVALUATION OF DEMINERALIZED
FREEZE DRIED BONE ALLOGRAFT (DFDBA) AND
GENGIGEL ALONG WITH A GUIDED TISSUE
MEMBRANE FOR THE TREATMENT OF GRADE II
FURCATION DEFECTS : A RANDOMISED
CONTROLLED CLINICAL TRAIL”**

By

Dr. ROHITA PENDYALA

REG. NO. I K0218002

Dissertation

Submitted to

*KLE Academy of Higher Education and Research,
Belagavi, Karnataka*

*In partial fulfilment
of the requirements for the degree of*

**MASTER OF DENTAL SURGERY
in
PERIODONTICS
(Branch II)**

Under the guidance of

Dr. ABHISHEK N. ZINGADE MDS

**DEPARTMENT OF PERIODONTICS
KAHE's KLE VISHWANATH KATTI INSTITUTE OF
DENTAL SCIENCES**

KAHER, BELAGAVI-590010, KARNATAKA

2018 - 2021

**KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH,
BELAGAVI, KARNATAKA**

Declaration by the Candidate

*I hereby declare that the dissertation “**COMPARATIVE EVALUATION OF DEMINERALIZED FREEZE DRIED BONE ALLOGRAFT (DFDBA) AND GENGIGEL ALONG WITH A GUIDED TISSUE MEMBRANE FOR THE TREATMENT OF GRADE II FURCATION DEFECTS: A RANDOMISED CONTROLLED CLINICAL TRAIL**” is a bonafide and genuine research work carried out by me under the guidance of **Dr. ABHISHEK N. ZINGADE** MDS, Reader, Department of Periodontics, KAHER’s KLE V. K. Institute of Dental Sciences, Belagavi.*

Date:

Place: Belagavi

Dr. ROHITA PENDYALA

**KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH,
BELAGAVI, KARNATAKA**

Certificate by the Guide

*This is to certify that the dissertation “**COMPARATIVE EVALUATION OF DEMINERALIZED FREEZE DRIED BONE ALLOGRAFT (DFDBA) AND GENGIGEL ALONG WITH A GUIDED TISSUE MEMBRANE FOR THE TREATMENT OF GRADE II FURCATION DEFECTS : A RANDOMISED CONTROLLED CLINICAL TRAIL**” is a bonafide research work done by **Dr. ROHITA PENDYALA** in partial fulfilment of the requirement for the degree of **Master of Dental Surgery (MDS) in Periodontics (Branch II)**.*

Date:

Place: Belagavi

Dr. ABHISHEK N. ZINGADE_{MDS}

Reader,

Department of Periodontics,
KAHER's KLE V. K. Institute of
Dental Sciences, Belagavi.

**KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH,
BELAGAVI, KARNATAKA**

**Endorsement by the Head of Department &
Principal / Head of the Institution**

*This is to certify that the dissertation “**COMPARATIVE EVALUATION OF DEMINERALIZED FREEZE DRIED BONE ALLOGRAFT (DFDBA) AND GENGIGEL ALONG WITH A GUIDED TISSUE MEMBRANE FOR THE TREATMENT OF GRADE II FURCATION DEFECTS : A RANDOMISED CONTROLLED CLINICAL TRAIL**” is a bonafide research work done by **Dr. ROHITA PENDYALA (IK0218002)** under the guidance of **Dr. ABHISHEK N. ZINGADE** MDS, Reader, Department of Periodontics, KAHER’s KLE V. K. Institute of Dental Sciences, Belagavi.*

Dr. VINAYAK KUMBHOJKAR MDS

Professor & Head,
Department of Periodontics,
KAHER’s KLE V. K. Institute of
Dental Sciences, Belagavi

Date:

Place: Belagavi

Dr. ALKA KALE MDS, PhD.

Principal,
KAHER’s KLE V. K. Institute of
Dental Sciences, Belagavi

Date:

Place: Belagavi

**KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH,
BELAGAVI, KARNATAKA**

Copyright Declaration

*I hereby declare that **KLE Academy of Higher Education and Research, Belagavi, Karnataka, shall have the rights to preserve, use and disseminate this dissertation entitled “COMPARATIVE EVALUATION OF DEMINERALIZED FREEZE DRIED BONE ALLOGRAFT(DFDBA) AND GENGIGEL ALONG WITH A GUIDED TISSUE MEMBRANE FOR THE TREATMENT OF GRADE II FURCATION DEFECTS : A RANDOMISED CONTROLLED CLINICAL TRAIL” in print or electronic format for academic/ research purpose.***

Date:

Place: Belagavi

Dr. ROHITA PENDYALA

© KAHER, Belagavi, Karnataka

[Established under section 3 of the UGC Act, 1956 vide GOI.

Notification No. F.9-19/2000-U.3(A)]

PLAGIARISM ACCEPTED LETTER

Scientific Correspondence and Review Committee



KLE VK Institute of Dental Sciences

A Constituent Unit of KLE Academy of Higher Education and Research
(Deemed-to-be-University u/s 3 of the UGC Act, 1956)

Nehru Nagar, Belagavi - 590 010, Karnataka State

Accredited 'A' Grade by NAAC (2nd Cycle)

Placed in Category 'A' by MHRD (GoI)

☎: 0831-2470362

Web: <http://www.kledental-bgm.edu.in>

FAX: 0831-2470640

E-mail: principal@kledental-bgm.edu.in

Date : 28-9-2020

Serial No. : 050

PLAGIARISM CHECK REPORT

Name of the Applicant : Dr. Rohita Pendyala
UG / PG / Ph.D / Staff : Post Graduate
Batch & Year : 2018-2021
Department : Periodontics

The soft copy of Research Work / Manuscript by Dr. Rohita Pendyala entitled "Comparative evaluation of demineralised freeze dried bone allograft (DFDBA) and gingival (GTR) along with a guided tissue regenerative membrane (GTR) for the treatment of grade II furcation defects."

under the guidance of has been submitted for Anti-Plagiarism check to the Scientific Correspondence & Review Committee of KLE VK Institute of Dental Sciences using "Turn-it-in" software.

The scan has been carried out and the scanned output reveals a Similarity Index of 3%, which is within / not within the acceptable limits of 10% as per the UGC guidelines.

Member Secretary

Scientific Correspondence and Review Committee
KLEVK Institute of Dental Sciences
KAHER-Belagavi

Chairman

Scientific Correspondence and Review Committee
KLEVK Institute of Dental Sciences
KAHER - Belagavi

BIostatISTICS CLEARANCE CERTIFICATE



KLE V.K. Institute of Dental Sciences

(A Constituent unit of KLE Academy of Higher Education & Research
Deemed-to-be-University u/s 3 of the UGC Act, 1956)
Nehru Nagar, Belagavi-590 010 INDIA

Re-Accredited 'A' grade by NAAC (2nd Cycle) & Placed in Category 'A' by MHRD (GoI)

☎ : 0831-2470362
FAX: 0831-2470640

Web: <http://www.kledental-bgm.edu.in>
E-mail: principal@kledental-bgm.edu.in



Biostatistics Clearance Certificate

This is to certify that the Biostatistics aspect of the Dissertation / Research work of.....*Dr. Rohita Pendyala*..... entitled.....*Comparative Evaluation of Demineralized Freeze Dried Bone allograft (DFDBA) and Gengigel along with a Guided Tissue Membrane for the treatment of GRADE II furcation defects: A RANDOMISED CONTROLLED CLINICAL TRIAL* has been done under my guidance and considered satisfactory.

Place : Belagavi

Date : *25/09/2020.*

Name & Signature of Biostatistician

(Dr. S. B. Javali)

UNDERTAKING

I, **DR. ROHITA PENDYALA** Post – Graduate student in the subject of **Periodontics** has completed research work on the topic “***COMPARATIVE EVALUATION OF DEMINERALIZED FREEZE DRIED BONE ALLOGRAFT (DFDBA) AND GENGIGEL ALONG WITH A GUIDED TISSUE MEMBRANE FOR THE TREATMENT OF GRADE II FURCATION DEFECTS : A RANDOMISED CONTROLLED CLINICAL TRAIL***”, in the year **2018-2021**.

I have been given to understand that any research work I undertake for the purpose of dissertation, oral presentation or publication during my study course shall be the property of the *KAHER Vishwanath Katti Institute of Dental Sciences, Belagavi*. Hence, I hereby declare that the name of the Department Institute and University shall be mentioned in my publications. The authorship shall be according to the guideline informed to me.

Date:

Place: Belagavi

Signature of the Student

UNDERTAKING

I, *Dr. ROHITA PENDYALA* hereby declare that the information and the data mentioned in my thesis entitled, *“COMPARATIVE EVALUATION OF DEMINERALIZED FREEZE DRIED BONE ALLOGRAFT(DFDBA) AND GENGIGEL ALONG WITH A GUIDED TISSUE MEMBRANE FOR THE TREATMENT OF GRADE II FURCATION DEFECTS : A RANDOMISED CONTROLLED CLINICAL TRAIL”* belongs to me and is original.

I am aware of the definition of plagiarism as detailed below:

- An act or instance of using or closely imitating the language and thoughts of another author without authorization and the representation of that author's work as one's own, as by not crediting the original author.
- A piece of writing or other work reflecting such unauthorized use or imitation.
- The deliberate or reckless representation of another's words, thoughts or ideas as one's own without attribution in connection with submission of academic work, whether graded or otherwise.

I hereby declare that the thesis prepared by me is an original one and does not involve plagiarism anywhere. In case at a later stage it is found that I have indulged in plagiarism, then I am solely responsible for the same and the institution is at liberty to take any disciplinary action against me including cancellation of dissertation or any other penalties imposed by the university.

Date:

Signature of the student

Place: Belagavi

ACKNOWLEDGEMENT

*I would like to start by thanking the **Almighty** for showering me with his blessings.*

*No words will be sufficient to thank my **Parents, Mr. Kondala Rao and Mrs. Leela Kumari**, and my brother **Phani Sandeep**. Their love, care, blessings, encouragement and invariable support right from the beginning till now has made me what I am today.*

*I express my sincere gratitude to my respected teacher and guide **Dr. Abhishek N. Zingade** MDS Reader, Department of Periodontics, KAHER's KLE V.K. Institute of Dental Sciences, Belagavi, to give me an opportunity to take this project. His constant encouragement, constructive criticism and valuable suggestions for improvement, have made completion of this work possible.*

*I am immensely indebted to my respected teacher **Dr. Vinayak Kumbhojkar** MDS, Professor and Head, Department of Periodontics, KAHER's KLE V.K. Institute of Dental Sciences, Belagavi, for his moral support, timely help and suggestions.*

*I would also like to thank **Dr. Alka Kale** MDS, PhD, Principal, KAHER's KLE V.K. Institute of Dental Sciences, Belagavi for providing me the required facilities and infrastructure.*

*I am extremely grateful to my revered and respected teachers **Dr. Shaila Kothiwale** MDS, PhD Professor, **Dr. Renuka Metgud** MDS, Professor, **Dr. Menaka K.B.** MDS Reader, **Dr. Neelamma Alatagi** MDS, Reader, **Dr. Vilas Pattar** MDS, Lecturer,*

Dr. Shweta Hugar MDS , Dr. Shruti Karvekar MDS, Lecturer, Dr. Anita Raikar MDS, Lecturer for their guidance, which has been a source of inspiration for learning.

*I sincerely thank **Dr. Javali**, for helping me with the statistical analysis and interpretation.*

*I also take pleasure in thanking my seniors **Nivedita, Reshma, Aditi and Asem** and also my juniors **Maria ,Nikitha, Alpana, Vishakha and Minal** for their co-operation and help whenever I needed it.*

*I would like to thank my friends **Dr.Chaitra , Dr.Harshali , Dr. Sravan , Dr. Sabira and Dr. Mohit** for their constant support and for always keeping my morale afloat.*

*I am very much indebted to this department and extend my appreciation to all the **non-teaching staff** of the department for their able assistance.*

*Last but not the least I would like to thank **Mr. Anand** and **Mr. Arun** who have patiently managed the formatting and printing of my dissertation.*

Dr. ROHITA PENDYALA

LIST OF ABBREVIATIONS

DFDBA	Demineralized Freeze Dried Bone Allograft
GTR	Guided Tissue Renegeration
RC	Root Concavity
RT	Root Trunk
FI	Furcation Involvement
CAF	Coronally Advanced Flap
CEJ	Cemento Enamel Junction
SBI	Sulcus Bleeding Index
PPD	Probing Pocket Depth
RAL	Relative Attachment Level
HFI	Horizontal Furcation Involvement
VFI	Vertical Furcation Involvement
UNC	University Of North Carolina
BOP	Bleeding On Probing
BMP	Bone Morphogenic Protein
FRP	Fixed Reference Point
GF	Growth Factor
TGF- 1	Transforming Growth Factor - 1

ABSTRACT

Background: Successful management of furcation involved tooth is a clinical challenge. Closure of furcation defects is the most desirable outcome of therapy to ensure optimal maintenance and long-term success. Attempts at regenerative therapy based on the concept of guided tissue regeneration (GTR) can result in significant improvements in clinical parameters, bone fill and closure of defects. Various biomaterials like DFDBA which has both osteoconductive and osteoinductive properties have been employed over years to achieve this goal . Various newer materials have also been used for this purpose. One such material is 0.8% hyaluronic acid (Gengigel[®]) which showed regenerative potential and also improvement in clinical parameters like clinical attachment level, pocket probing depth etc.

Objective: To compare and evaluate the use of DFDBA and 0.8% Gengigel[®] along with a GTR for the treatment of Grade II furcation defects.

Materials and methods: Thirteen patients presenting bilateral mandibular Grade II furcations were included. Sites were allotted either Group A (DFDBA+GTRcollagen membrane (HEALIGUIDE[®]) or Group B (0.8%Gengigel[®]+GTR collagen membrane (HEALIGUIDE[®]). Clinical Parameters such as Sulcus Bleeding Index (SBI), Probing Pocket Depth (PPD),Relative Attachment Level (RAL) were assessed at baseline, 1 month, and 6 months. Horizontal Furcation Involvement and Vertical Furcation Involvement were assessed at baseline, 1month and 6 months.

Results: Intra group comparison showed statistically significant improvement in all clinical parameters with mean bone fill of 1.45 ± 0.86 and 1.50 ± 0.58 in Group-A and

Group-B respectively. Inter group comparison showed no statistically significant difference when the two groups were compared at 6 months.

Conclusion: 0.8% Gengigel gives promising results that are comparable and almost equivalent to DFDBA .

Keywords: Grade II furcation, Demineralized Freeze Dried Bone Allograft (DFDBA), 0.8% Gengigel[®], Guided Tissue Regenerative Membrane (GTR), Healiguide[®], bone regeneration.

TABLE OF CONTENTS

SL NO.	PARTICULARS	PAGE NO.
1	INTRODUCTION	1-4
2	AIM AND OBJECTIVES	5
3	REVIEW OF LITERATURE	6-34
4	MATERIALS AND METHODS	35-48
5	RESULTS AND OBSERVATIONS	49-70
6	DISCUSSION	71-81
7	SUMMARY AND CONCLUSION	82-83
8	BIBLIOGRAPHY	84-95
9	ANNEXURES	96-104

LIST OF TABLES

TABLE NO.	PARTICULARS	PAGE NO.
1	Gender wise distribution.	50
2	Comparison of Group A and Group B with mean age by Independent t- test	50
3	Comparison of Group A and Group B with Sulcus Bleeding Index at baseline, 1month and 6months time points by Independent t-test.	51
4	Comparison at baseline , 1month and 6months time points with Sulcus Bleeding Index in Group A and Group B by Kolmogorov Smirnov	52
5	Comparison of group A and group B with Probing Pocket Depth at baseline , 1month and 6months time points by Independent t test.	55
6	Comparison of baseline, 1 month and 6months time points with Probing Pocket Depth in Group A and Group B by Kolmogorov Smirnov	56
7	Comparison of Group A and Group B with Relative Attachment Level at baseline , 1month and 6months time points by Independent t test.	59
8	Comparison of baseline, 1month and 6months time points with Relative Attachment Level in Group A and Group B Kolmogorov Smirnov	60
9	Comparison of Group A and Group B with Horizontal Furcation Involvement at baseline, 1month and 6months time points by Independent t- test	63

10	Comparison of baseline, 1month and 6months time points with Horizontal Furcation Involvement in Group A and Group B by Kolmogorov Smirnov	64
11	Comparison of Group A and Group B with Vertical Furcation Involvement at baseline , 1month and 6months time points by Independent t-test.	67
12	Comparison of baseline, 1month and 6months time points with Vertical Furcation Involvement in Group A and Group B Kolmogorov Smirnov	68

LIST OF GRAPHS

GRAPH NO.	PARTICULARS	PAGE NO.
1	Gender wise distribution	53
2	Comparision of group A and group B with relative attachment level (mm) at baseline, 1 month and 6 months time points	53
3	Comparision of group A and group B with pocket probing depth (mm) at baseline, 1 month and 6 months time points	57
4	comparision of at baseline,1 month and 6 months time points with pocket probing depth (mm) in group A and group B	57
5	Comparision of group A and group B with relative attachment level (mm) at baseline, 1 month and 6 months time points	61
6	Comparision of at baseline, 1 month and 6 months time points with relative attachment level (mm) in group A and group B	61
7	Comparision of group A and group B with horizontal furcation involvement at baseline, 1 month and 6 months time points	65
8	Comparision of at baseline, 1 month and 6 months time points with Horizontal furcation involvement in group A and group B	65
9	comparision of group A and group B with vertical furcation involvement at baseline, 1 month and 6 months time points	69
10	comparision of at baseline, 1 month and 6 months time points with vertical furcation involvement in group A and group B	69

LIST OF FIGURES

SR. NO.	PARTICULARS	PAGE NO.
1.	Armamentarium	44
2.	Materials Used For Study	44
3.	Surgical procedure for GROUPA (DFDBA+GTR) and post-operative recall at 1month and 6 month.	45-46
4.	Surgical procedure for GROUP B (Gengigel+GTR) and post-operative recall at 1month and 6 month.	47-48

LIST OF ANNEXURES

SL. NO.	PARTICULARS	PAGE NO.
1.	Ethical Clearance Certificate	96
2.	Consent form	97-101
3.	Proforma	102-104

INTRODUCTION

Periodontitis is defined as “an inflammatory disease of supporting tissues of teeth caused by specific microorganisms or groups”^[1]. This will result in a progressive destruction of the periodontal ligament and alveolar bone which leads to the appearance of the clinical signs of periodontitis. Periodontal diseases are considered to be one of the most prevalent diseases and are the major cause of tooth morbidity and mortality. Hence, “the ultimate goal of periodontal therapy is to arrest the disease progression and to achieve a healthy and functional periodontium that helps in the long term maintenance of the dentition throughout lifetime”^[2].

Furcation involvement is one of the major consequence of the progression of periodontitis and increases the risk of tooth loss. . Furcation involvement is common with an incidence of 35% in mandibular molars and 90% in maxillary molars. Bacterial invasion and subsequent destruction of the surrounding structures leading to furcation invasion making it inaccessible for proper maintenance and long-term stability of the tooth. Furcation involved tooth shows greater amount of clinical attachment loss as compared to single rooted teeth^[3] .

The extent of furcation involvement is often difficult to diagnose, and therefore a combination of radiographs, clinical probing with Nabers probe, and bone sounding must be done simultaneously^[4]. The management of multi-rooted teeth demonstrating furcation involvement is one of the greatest clinical challenges to the periodontist. The suggested treatment modalities for furcation defects include odontoplasty, open flap debridement, regeneration, root resection, and extraction.

Regenerative therapies have been aimed at not only closing the furcation by filling it, but more specifically by attaining a gain in periodontal attachment apparatus to reduce and eliminate the defect^[5]. With the introduction of bioactive agents, such as platelet concentrates (PCs), enamel matrix derivatives (EMD), bone morphogenic proteins (BMP), and matrix macromolecules such as hyaluronic acid (HA) the scope for better outcomes in furcation treatment has been surfaced.

Regeneration of new bone, cementum and periodontal ligament has also been documented histologically in humans by Bower in 1989^[6]. Bone allografts has been referred to as a gold standard for grafting procedures but their use is limited because of insufficient intra-oral graft and post-operative complication due to secondary donor site^[4].

Urist and Strates (1965) stated that demineralising and freeze drying the bone increases the osteogenic potential by removing the mineral content and exposing the BMP present. Among them demineralised freeze dried bone allograft (DFDBA) has shown a potential to reconstruct the intraosseous periodontal and furcation defects clinically as well as histologically^[7].

Demineralized freeze-dried bone allograft was first used by LIBIN in 1975 and has been used for more than three decades from then. Thus, they have been used to reconstruct intraosseous periodontal and furcation defects^[8].

Despite the presence of BMP in DFDBA, direct clinical comparison of treatment success using mineralized freeze–dried bone allografts and DFDBA yielded similar results. So, DFDBA if not osteoinductive can be considered at least osteoconductive scaffold with limited bone inductive proteins^[9].

In 1976, Melcher presented the basic concepts of compartmentalisation, which led to the development of the clinical technique known as guided tissue regeneration (GTR). The use of barrier membrane enhances the regeneration by grafting which excludes gingival fibroblasts and epithelium from the healing site^[10]. This treatment modality allows for the formation of bone, cementum, and periodontal ligament in the degranulated periodontal defects by placement of a membrane which acts by selective prevention of epithelial cells from populating and thus enhancing the healing process.

Various non-resorbable and resorbable barrier membranes have been used for this purpose which forms a seal over the underlying bone graft which inhibits epithelial cell migration and promotes connective tissue attachment^[11]. Therefore, guided tissue regeneration using a membrane holds to be promising for increasing the success of bone grafting. When nonabsorbable membranes are used for guided tissue regeneration (GBR), second surgeries are required for membrane retrieval. In addition, these types of membranes show a high incidence of flap sloughing and membrane exposure that often lead to infection and unfavourable results. Absorbable barriers such as collagen membranes were developed to overcome these drawbacks.

Management of grade II furcation defects with osseous grafting and guided tissue regeneration enhances the response to membrane-only therapy^[8], with bone restoration via the conductive effect of the graft. In human Grade II furcations the addition of a bone graft in combination with a barrier has demonstrated improved bone density, probing depth reduction, and clinical attachment gain.

In cases of furcation involvement various new materials have been used for the advancement of naturally occurring extracellular matrix of connective tissue, synovial fluid and other tissues. Hyaluron has structural and physiological function

within tissue including cellular and extracellular interactions, growth factor interactions, regulation of osmotic pressure and tissue lubrication which helps in maintaining homeostatic integration of all tissues. Hyaluronate has shown anti-inflammatory, anti edematous, and anti-bacterial properties, which suggests their use for resolution of gingivitis and periodontitis. Hyaluronic acid have shown osteoconductive potential by accelerating bone regeneration with means of chemotaxis, proliferation and successive differentiation of mesenchymal cells. Bone induction characteristics are comparable to BMP-2 and osteopontin^[12].

Hyaluronin(gengigel) is available in two formulations (0.2% & 0.8% concentration). 0.2% is used for the treatment of gingivitis where as 0.8% when used after mechanical debridement has major clinical benefits of improved healing after non-surgical therapy^[13]. The regenerative potential of gengigel has been tested for vertical bony defects, extraction sockets, wound healing and so on.

The present study is therefore undertaken to comparatively evaluate the Demineralized Freeze Dried Bone Allograft (DFDBA) and GENGIGEL[®] along with a guided tissue membrane for the treatment of Grade II furcation defects.

AIMS AND OBJECTIVES OF THE STUDY

AIM OF STUDY

To compare and evaluate the use of Demineralized Freeze Dried Bone Allograft(DFDBA) and Gengigel[®] (0.8%) along with a Guided Tissue Regenerative Membrane(GTR) for the treatment of Grade II furcation defects.

OBJECTIVES OF STUDY

- To clinically evaluate Bleeding Index, Relative Attachment Level, Pocket Probing Depth with the use of Demineralized Freeze Dried Bone Allograft(DFDBA) and Guided Tissue Regenerative Membrane(GTR) for treatment of Grade II furcation defects.
- To radiographically evaluate the percentage of bone fill with the use of Demineralized Freeze Dried Bone Allograft(DFDBA) and Guided Tissue Membrane(GTR) for treatment of Grade II furcation defects
- To clinically evaluate bleeding index, relative attachment level, pocket probing depth with the use of Gengigel[®] (0.8%) of and Guided Tissue Regenerative Membrane(GTR) for treatment of Grade II furcation defects.
- To radiographically evaluate the percentage of bone fill with the use of Gengigel[®] (0.8%) and Guided Tissue Regenerative Membrane(GTR) for treatment of Grade II furcation defects.
- To compare the effect of Demineralized Freeze Dried Bone Allograft(DFDBA) and Gengigel[®] (0.8%) along with a Guided Tissue Regenerative Membrane(GTR) for treatment of Grade II furcation defects .

REVIEW OF LITERATURE

FURCATION DEFECTS

A furcation invasion / involvement (FI) has been defined by the American Academy of Periodontology as the pathologic resorption of bone in the anatomic area of a multi-rooted tooth where the roots diverge. It typically occurs due to the progression of chronic or aggressive periodontitis^[14].

In a landmark study by Hirschfeld and Wasserman, it was observed that teeth with furcation involvement exhibited a higher rate of tooth loss (31%) compared to teeth without furcation defects (7%) over a period of 15 years^[15]. In addition, several studies have demonstrated that FI tooth responded less favourably to non-surgical therapy than tooth without FI.

Prevalence and distribution:

Furcation involvement is frequently more common in maxillary molars than in mandibular molars (Ross & Thompson 1980, Svardstrom & Wennstrom 1996, Dannewitz et al., 2006)^[16]. A study by Ross and Thompson (1980) found that the prevalence of furcation involvement in maxillary molars was 90%; compared with 35% in mandibular molars^[17]. Studies on dry skulls have found that maxillary first and second molars have a higher risk for furcation involvement than mandibular molars. Moreover, first molars were more frequently affected than second molars (Larato 1970, Tal & Lemmer 1982)^[19]. According to Svardstrom (1996), highest frequency of furcation involvement is the distal of maxillary 1st molar (53%) and lowest frequency of furcation involvement is the mesial of the maxillary 2nd molar(20%)^[20].

Etiology

The etiology of furcation involvement maybe classified into three major groups^[21].

1. Primary factor - Bacterial plaque, most common etiologic factor
2. Predisposing factors - Location relative to cementoenamel junction (CEJ), root trunk length, root length, root form, interradicular dimension, furcation shape, location of entrance, furcation entrance diameter, facial and lingual radicular bone, enamel projections, enamel pearls, bifurcation ridges, root concavities, and carious lesions.
3. Contributing factors - plaque-associated inflammation, trauma from occlusion, pulpal pathology, vertical root fractures, and iatrogenic factors.

Diagnosis

1. Clinical Assessment
2. Probing: Buccal and lingual furcation can be easily probed. Proximal furcations are difficult for probing particularly when broad contacts are present in adjacent teeth. Nabers Probe and Columbia curette 4R/4 L are used for probing the furcation area
3. Bone Sounding or Transgingival probing: It may aid in the diagnosis of furcation defects more accurately determining the underlying bone contours.
4. Radiographic Assessment- Radiographs have been used to determine the presence or absence of FI with different results (Rees et al., 1971, Deas et al., 2006)^[22]. Rees et al., found that 86% of the buccal and lingual furcation can be diagnosed with the aid of radiographs. Deas et al., found that the agreement on detection of proximal FI between clinical and radiographic examination.

Classification^[23]

A number of classifications have been proposed to categorize furcation involvement.

Various Classifications proposed for Furcation Involvement

AUTHOR(S)	CLASSIFICATION
1958 Glickman^[24]	Grade I: soft tissue lesion extending to the entrance of the furcation but no furcal bone loss Grade II: loss of furcal bone to varying degrees but not through and through Grade III: through and through but not clinically visible (presence of granulomatous tissue) Grade IV: through and through visible clinically (tunnel)
1958 Goldman^[25]	Grade I: incipient Grade II: cul-de-sac (pouch) Grade III: through and through
1969 Staffileno^[26]	Grade I: soft tissue lesion extending to the entrance of the furcation with minor degree of bone loss Grade II: loss of furcal bone but not through and through Grade III: through and through
1969 Easley and Drennan^[27]	Class I: incipient involvement, entrance of the furcation detectable with no horizontal bone loss Class II, Type 1: horizontal bone loss but no vertical component Class II, Type 2: horizontal bone loss and vertical bone loss Class III, Type 1: through-and-through bone loss with no vertical component Class III, Type 2: through-and-through bone loss with vertical component
1975 Hamp et al^[28]	Degree/Class I: horizontal loss of periodontal tissue support <3 mm Degree/Class II: horizontal loss of periodontal tissue support >3 mm but not

	through and through Degree/Class III: through-and-through defect
1979 Ramfjord ^[29]	Degree 1: horizontal penetration <2 mm Degree 2: horizontal penetration >2 mm but not through and through Degree 3: through and through
1982 Ricchetti ^[30]	Class I. 1 mm of horizontal measurement; the root furrow. Class Ia. 1–2 mm of horizontal invasion; earliest damage. Class II. 2–4 mm of horizontal invasion. Class IIa. 4–6 mm of horizontal invasion Class III. > 6 mm of horizontal invasion
1984 Tarnow and Fletcher ^[31]	Uses Grades I, II, III proposed previously by Glickman with an additional sub-classification based on vertical invasion from the furcation fornix: A: VPD, 1 to 3 mm B: VPD, 4 to 6 mm C: VPD, >7 mm
1998 Hou et al ^[32]	Three classes (Class I, II, and III): Classes are the same as Grades in the classification by Hamp et al., Two subclasses (Subclass a and b): a: for suprabony defects b: for infrabony defects Three types (A, B, and C): A: root trunk represents the cervical one-third of the root complex B: root trunk represents half of the root complex C: root trunk represents the cervical two-thirds of the root complex

The present study deals with Grade II furcation defects, as classified by Glickman, demonstrating loss of furcal bone to varying degrees but not through and through. Nevertheless, the classification by Hamp et al., is probably the most universal one. This is likely attributable to its simplicity and the correlation between the proposed degrees of severity and commonly found clinical scenarios; also, it is the most commonly used classification in periodontal research.

Management

The treatment or correction of a furcation invasion is dependent on several factors such as, the severity of furcation invasion, amount of remaining bone support, status of abutment teeth, and strategic importance of the involved tooth. Grade I lesions frequently respond well to conservative therapy that involves odontoplasty, non-surgical therapy, and minimal flap surgery. Grade III/ IV lesions are managed by surgical therapy such as Widman flaps or tunnel preparations, root resections, and hemisection. Grade II furcation defects respond well to regenerative therapies^[33].

In a recent systematic review by Avila-Ortiz et al., (2015)^[34] it was concluded that the indication of regenerative approaches for the treatment of furcation defects is predictable in certain clinical scenarios, particularly in maxillary facial or interproximal and mandibular facial or lingual Class II furcation defects. Regenerative therapy in maxillary molars presenting Class III furcation defects and in maxillary premolars affected by Class II or III furcation defects is not predictable based on current available evidence. The authors also stated that, novel approaches such as, tissue engineering-based approaches consisting of the application of biologic agents, growth factors, scaffolds, pluripotential cells or a combination.

Regeneration is defined as the reproduction or reconstitution of a lost or injured part in such a way that the architecture and function of the lost or injured tissues are completely restored^[3]. Although many attempts have been made to regenerate alveolar bone support and the attachment apparatus, predictable success has proved elusive. Osseous grafts are the only material for which ample histologic evidence is available for periodontal reconstruction in humans, including new cementum, alveolar bone, and a functional periodontal ligament.

Periodontal bony defects are treated because they complicate the definitive elimination of active pocket defects, compromise the support of the tooth and the tooth's ability to withstand functional stresses and complicate maintenance of an arrested pocket defect. The ideal result is correction of bony defects by regeneration of lost supporting bone and periodontal ligament. Furthermore, there is evidence that supracrestal bone regeneration is possible when certain bone replacement grafting materials are used. This has not been observed with other forms of regenerative periodontal therapy, which attempt to eliminate bony defects without a bone replacement graft material.

The objectives of periodontal bone grafts are^[35]:

1. Probing depth reduction
2. Clinical attachment gain
3. Bone fill of the osseous defects
4. Regeneration of new bone, cementum and periodontal ligament.

The ideal graft material remains to be found, such a material induces osteogenesis and cementogenesis that would result in regeneration of a new periodontal attachment complex at a more coronal level. It would be completely biocompatible and would not be carcinogenic, toxic or antigenic or effect round-cell infiltration responses. It would also be easily obtainable, relatively inexpensive and would not cause the patient or the therapist unnecessary inconvenience.

The three types of grafts being used most frequently today in periodontics are autogenous grafts, allografts and alloplasts^[35].

Allografts are grafts transferred between genetically dissimilar members of the same species. Demineralized freeze-dried bone allograft induces host mesenchymal cells to differentiate into osteoblasts (Harakas). Urist et al showed that demineralization and freeze- drying of cortical bone graft material greatly enhances its osteogenic potential. HCl demineralization exposes the bone morphogenic proteins that are composed of acidic polypeptides. The bone morphogenic proteins are located in the bone matrix and therefore are abundant in cortical bone where bone matrix is more abundant. The use of DFDBA in human periodontal defects was first reported by Libin et al (Libin et al 1975)^[36].

Particle size of DFDBA ranging from 45 μ to 1000 μ are currently available and in use. Factors related to particle size that cause differences in healing include interparticle spacing, surface area and exfoliation of osseous graft particles. Shape and size of the particles can affect interparticle spacing of approximately 40 μ - 200 μ is necessary for the ingrowth of vascular and bony tissue (Zaner DJ et al 1984)^[37]. A greater surface area to volume ratio could potentially expose more of the growth and differentiation factors in the collagenous matrix of the graft and enhance the early

stages of healing. Narrower spaces may inhibit revascularization and retard healing. However particle size did not correlate with the ability to induce bone. Commercial DFDBA preparations differ in both size and ability to induce new bone formation, but these two are not related^[38].

STUDIES ON DFDBA

Barry M. Libin et al (1975)^[39] presented three reports of patients with severe periodontal defects treated with a decalcified, lyophilized bone allograft prepared as described by Urist. Two patients received grafts of cancellous bone and one patient received a cortical bonegraft. The patients were observed up to 2 years following implantation. Clinical and histological data concluded that the implantation of decalcified, lyophilized bone allograft of both the cortical and cancellous bone types resulted in new bone formation and a gain in attachment level and no evidence of rejection of graft material for up to 2 years following implantation.

GE Pearson, S.Rosen and D.A Deporter (1981)^[40] performed a controlled pilot study to evaluate the effectiveness of decalcified freeze-dried cancellous bone allograft material in the treatment of intrabony periodontal defects in humans. 22 defects were selected for the study, out of which 16 defects were randomly selected for grafting while the remaining 6 served as controls. Significant gains in attachment were achieved with the allografting procedure but not with the control procedure, which consisted of flap and curettage only.

Quintero et al (1984)^[41] evaluated the osteogenic potential of DFDBA in the treatment of human periodontal osseous defects over a 6-month period. Cortical bone obtained under sterile conditions from a human donor within 24 hours after death, was

decalcified, freeze dried and grounded to particle size of 250-500 microns. 27 osseous defects with one, two and wide three wall morphology were treated. Clinical measurements were made before surgery, at the time of surgery and re-entry. The combined mean osseous regeneration for all defects was 2.4mm. This represented a 65% mean bone fill of the original defect. In conclusion DFDBA has a potential as an osseous grafting material in periodontal therapy.

Mellonig et al (1984)^[42] compared open flap debridement plus DFDBA (32 defects) versus open flap debridement alone (15 defects) for the treatment of intrabony defects. Grafted defects had an average depth of 4.0 ± 1.6 mm, clinical attachment level gain at an average 2.9 ± 1.3 mm and bone gain 2.6 ± 1.4 mm, which were significantly better than open flap debridement.

Gerald M Bowers et al (1985)^[43] this study was designed to evaluate the potential for regeneration of a new attachment in patients whose attachment apparatus has been destroyed by periodontal disease. In each of the three parts of the investigation, the most apical level of calculus on the root served as a histologic reference point to measure regeneration. In part I, attempts were made to initiate the formation of new attachment by surgical debridement, crown removal and submersion of the vital root below the mucosa. In part II the debrided intra bony defects were treated with or without DFDBA and the associated vital roots were submerged. Part III evaluated the potential for regeneration of a new attachment in non-submerged roots with and without use of DFDBA. Gingival grafts were placed. Biopsies were obtained in 6 months and regeneration was evaluated histometrically. Preliminary results in 24 defects indicated that new attachment is possible on pathologically exposed roots surfaces in a submerged environment with and without the incorporation of DFDBA.

New attachment was observed on pathologically exposed root surfaces in a submerged environment when intrabony defects were grafted with DFDBA. New attachment was not observed on non-grafted, non-submerged defects irrespective of placement of gingival grafts over the defects.

Marvin Werbitt (1987)^[44] presented several case reports where DFDBA had been used to treat advanced intrabony defect and where new bone formation had occurred. A total of 20 defects were treated, and at the nine-month evaluation, the six cases presented in this report had minimal probing depth and showed radiographic evidence of substantial bone fill. The amount of repair ranged from 75% to 95% of the original defect. Bone fill was achieved on both vital and non-vital teeth and in some cases there was a radiographic evidence of a lamina dura and a discernable periodontal ligament space. Furthermore, the teeth that were initially mobile showed a decrease in mobility.

James A Bowen et al (1989)^[45] compared healing potential of the osteoinductive DFDBA with an osteoinductive porous hydroxyapatite (HA). 6 patients were selected for the study. Soft and hard tissue measurements were taken at baseline and 6 months re-entry. There was no significant difference in any of the soft tissue measurements when DFDBA and HA were compared. There was a defect fill of 61% for DFDBA and 53% for HA. These values were likewise not statistically different.

Gerald M Bowers et al (1989)^[27] compared the healing of intrabony defects with and without the placement of DFDBA in a submerged environment. Biopsies were obtained at 6 months and evaluated histometrically. Data from 9 patients with 30 grafted defects and 13 non-grafted defects showed results indicating that in a submerged environment, significantly more new attachment apparatus and new bone

was formed at grafted than non-grafted sites. Significantly greater loss of alveolar crest height occurred at non-grafted than grafted sites; regeneration of new attachment apparatus, new bone and new cementum occurred more frequently at grafted than non-grafted defects.

Gerald M Bowers et al (1989)^[46] compared the healing of intrabony defects with and without the placement of DFDBA in a non-submerged environment. Free gingival grafts were placed over grafted and non-grafted defects to retard epithelial migration. Biopsies were obtained at 6 months and regeneration was evaluated histometrically. Data from 12 patients with 32 grafted and 25 non-grafted defects showed results indicating, new attachment apparatus was observed when treated with DFDBA. Significantly more new attachment, new cementum, new connective tissue and new bone formed in intrabony defects treated with DFDBA than in non-grafted defects. Free gingival grafts did not enhance regeneration of new attachment apparatus, new cementum or new connective tissue. New cellular cementum formed on old cementum. Periodontal ligament was more frequently oriented perpendicular to the root. There was greater loss in alveolar crest height in non-grafted than grafted defects. Extensive root resorption, ankylosis and pulp death were not seen in both the grafted or non-grafted defects.

J.M Rummelhart et al (1989)^[47] compared freeze-dried bone allograft (FDBA) with demineralized freeze-dried bone allograft (DFDBA). 22 defects in 9 patients were grafted with either DFDBA or FDBA. Evaluations were based on standardized radiographs, presurgical and post surgical measurements using the cemento-enamel junction as fixed reference point and osseous measurements at the time of surgery. At reentry after 6 months a mean osseous repair of 59% occurred with DFDBA and 66%

with FDBA. Findings revealed significant differences between the two materials in primarily intraosseous defects when evaluated at a minimum 6 months post surgery.

James.T.Mellonig, Annamarie.B.Prewett & Mary Pat Moyar (1992) ^[48] conducted the study to obtain direct evidence that the processing of a DFDBA would render the allograft safe for human use. In part I, human cortical bone was obtained from a cadaveric source and tested to be free of HIV contamination. In part II, cortical bone was procured from a donor who died of AIDS. Test samples were treated with a virucidal agent and demineralized with HCl. Control samples were left untreated. All samples were co cultivated. Treated samples were negative when assayed for HIV. Bone samples in part II HIV infected bone, were positive by polymerase chain reaction. Replication of viable HIV could not be demonstrated after treatment. It was concluded that demineralization and treatment with a virucidal agent inactivates HIV in spiked and infected bone.

Stephen E. Fucini et al (1993) ^[49] conducted a study to compare the bony defect resolution obtained using 2 different particle size of DFDBA. Cortical bone from a single donor was processed and grounded to final particle sizes of 250 μ to 500 μ or 850 μ to 1000 μ . Paired interproximal intrabony periodontal defects in 11 patients were grafted with DFDBA. Soft and hard tissue measurements were made using an electronic constant force probe at the initial and reentry surgeries. Treated sites in 10 patients were reevaluated by reentry approximately 6 months post operatively. Mean bony defect fill was 1.66 mm for large particle group and 1.32 mm for the small particle group. There was no statistically significant difference in bony fill between defects grafted with the different particle sizes of DFDBA when used in humans.

Craig L Meadows et al (1993)^[50] compared the effectiveness of polylactic acid granules as an alloplastic grafting material to that of DFDBA and a flap procedure for debridement without graft (FPD). 10 patients with at least 3 similar periodontal osseous defects were included in the study group. Soft tissue and hard tissue measurements were determined at baseline and 6 months re-entry. No statistically significant differences were found in soft tissue recession between groups or in osseous defect measurements between polylactic acid granules and FPD. A statistically significant improvement was found in the fill of the osseous defects when using DFDBA compared to the other 2 groups. DFDBA produced the greatest amount of osseous defect fill, FPD less fill, and PLA the least amount of fill.

Yoichiro Shigeyama (1995)^[28] the studies described here focused on establishing biological activity of proteins extracts prepared from commercially obtained bone graft material in vitro. Furthermore, the biological activity of these proteins extracts in vitro was compared with similar extracts prepared from freshly obtained human bone. Biological activities of the bone matrix proteins examined included their ability to promote proliferation, attachment, and migration of gingival fibroblasts using in vitro system. Slot blot analysis revealed that commercially available material contains Type I collagen; fibronectin and BMP- 2, 4 & 7. The freshly prepared bone extracts appeared to have higher BMP concentrations. The ability of commercial extracts to promote cell proliferation, while significant was limited and less when compared to freshly obtained bone. All extracts promoted cell attachment significantly while none of these extracts promoted cell migration. Thus commercially prepared material retained proteins having capacity to influence cell behavior in vivo.

Francis et al (1995)^[51] evaluated an allogenic bone matrix (ABM) as a graft material for the treatment of periodontal osseous defects. Paired osseous defects in 11 patients were randomized to receive ABM or DFDBA. Soft tissue and hard tissue measurements were determined at baseline and 6 months reentry procedure. Standardized radiographs were taken. Results of radiographic analysis suggested similar density changes with each graft. These results demonstrated that both the treatments were effective and that ABM may be a useful graft material in the treatment of periodontal osseous defects.

Mark A Reynolds et al (1996)^[52] conducted a study to histologically examine the fate of DFDBA used for regeneration in intrabony defects. Histologic sections obtained from 12 patients with 32 grafted defects revealed that 72% of the grafted defects exhibited residual DFDBA particles. Data from 5 patients with 14 grafted sites permitted an intra subject comparison of the amount of regeneration in relation to the presence or absence of residual graft material. Defects harboring residual graft particles exhibited significantly greater amounts of new attachment apparatus formation. No apparent differences were seen in the nature of the new attachment apparatus or component tissues, other than in amount of formation.

J. de La Fontaine (1997)^[53] conducted a study to assess variability in osteoconduction of demineralized freeze dried bone allograft (DFDBA) obtained from multiple bone banks, and to develop an in vitro assay for predicting osteoinduction in vivo. Twelve lots of DFDBA obtained from six bone banks, were evaluated for osteoinduction in vivo following graft placement in mice. 8 lots were inductive, while 4 induced neither bone nor cartilage. An in vitro assay system for DFDBA induction activity was developed by first characterizing the response of the mesenchymal cell line 2T9 to an

established induction factor. Based on this study osteoinduction by DFDBA varies between bone banks as well as between lots of the same bank. The variation may be the results of factors, which affect the availability of bone induction proteins present in DFDBA. Alternatively, DFDBA may contain factors, which modify the response of target cells to bone induction proteins.

Parashis et al (1998)^[54] performed a study to compare clinically and radiographically the effectiveness of guided tissue regeneration, using a bioabsorbable polylactic acid softened with citric acid ester barrier and commercially available DFDBA in the treatment of 2 and 3 wall intrabony defects. 12 patients, each with one treated defect comprised each group. Soft tissue measurements and hard tissue measurements were taken and were comparable in both the groups at baseline. They were repeated at 12 months. Results showed no statistical significant differences between the 2 groups, only the exception was in the radiographic resolution of defect, which was significantly greater in the GTR group.

Graig D Brown et al (1998)^[55] conducted a study to determine the potential of hydroxyapatite cement for the treatment of periodontal osseous defects. 16 patients with 2 bilaterally symmetrically vertical defects received initial therapy followed by treatment with calcium phosphate cement, flap curettage (f/c) or debridement plus DFDBA. Soft tissue, hard tissue, measurements and standardized radiographs were taken at base line and 12 months. Results showed that mean probing depth reduction, clinical attachment level gain and defect fill at sites treated with calcium phosphate cement were minimal when compared to sites treated with DFDBA and (f/c). Based on this study there was no rationale available to support the use of hydroxyapatite

cement implant in its current formulation for the treatment of vertical intrabony periodontal defects.

Lars Laurell et al (1998)^[56] reviewed the studies presented during the last 20 years on the surgical treatment of intrabony defects. The treatments included open flap debridement, open flap debridement with DFDBA, freeze-dried bone allograft (FDBA) or autogenous bone and guided tissue regeneration (GTR). The review included only those studies that presented baseline and final data on probing depths, intrabony defect depth as measured during surgery, clinical attachment level gain and or bone fill. Result of meta-analysis showed that open flap debridement alone resulted in limited pocket reduction, clinical attachment level gain averaged 1.5mm and bone fill 1.1mm. Open flap debridement plus bone graft resulted in limited pocket reduction; clinical attachment level gain and bone fill averaged 2.1mm. Guided tissue regeneration resulted in significant pocket reduction, clinical attachment level gain of 4.2mm and bone fill averaging 3.2mm.

Staurt Froum et al (2002)^[57] compared healing extraction sockets 6 to 8 months post implantation of a bioactive glass or DFDBA to an unfilled socket control. 30 sockets in 19 patients were randomly divided into 3 treatment groups. 10 sockets received bioactive glass, 10 sockets DFDBA, and 10 sockets served as unfilled controls, and histological cores of the treatment sites were obtained. Results concluded that although the differences in percent vital bone were not statistically significant among the 3 treatment group, bioactive glass material was observed to act as an osteoconductive material and had a positive effect on socket healing at 6 to 8 months post extraction. Residual implant material was significantly higher in DFDBA treated sockets versus bioactive glass treated sockets.

Mark A Reynolds et al (2003)^[58]systemically reviewed the efficacy of bone replacement grafts in proving demonstrable clinical improvements in periodontal osseous defects compared to surgical debridement alone. The therapeutic end points examined included changes in bone level, clinical attachment level, probing depth, gingival recession and crestal resorption with respect to the treatment of intrabony defect, the results of meta-analysis supported the following conclusions;

1. Bone grafts increased bone level, reduced crestal resorption, increased clinical attachment level, and reduce probing depth compared to open flap debridement (OFD) procedures. 2) Bone grafts in combination with barrier membranes increased clinical attachment level and reduced probing depth compared to graft alone 3) Histologically DFDBA, supported the formation of a new attachment apparatus in intrabony defects, whereas OFD resulted in repair characterized by long junctional epithelium. The results of this systemic review indicated that bone replacement grafts provided demonstrable clinical improvement in periodontal osseous defects compared to surgical debridement alone.

Gurinsky BS et al (2004)^[59]conducted a study to evaluate the use of DFDBA in combination with Enamel matrix derivative compared to enamel matrix derivative alone in the treatment of human periodontal osseous defects. 40 patients with a total of 67 sites were selected for the study; each subject received either enamel matrix derivative alone, (34 sites) or enamel matrix derivative in combination with DFDBA (33 sites). Both soft tissue and hard tissue measurements were taken at baseline and 6 months. Results showed significant improvements in soft tissue parameters for both

treatment groups as compared to preoperative measurements. There was no statistical difference between the two groups.

Mary.E.Aichelmann-Reidy, Carlette.D.Heath & Mark.A.Reynolds (2004)^[60] conducted a study to establish whether there was a significant difference in hard tissue fill of intrabony defects following treatment with either calcium sulphate or ePTFE in combination with DFDBA. 19 patients with 38 defects were selected for the study. Soft tissue and hard tissue measurements were recorded at baseline and 6 months. Defects were randomly treated with either a combination graft of DFDBA with calcium sulphate covered by a calcium sulphate barrier or with DFDBA and fitted with an ePTFE barrier. Results of this study indicated that calcium sulphate, when used as a binder and barrier in combination with DFDBA, supported significant clinical improvement in intrabony defects. Calcium sulphate represented an alternative to non-resorbable ePTFE barrier in combination with DFDBA for the treatment of intrabony defects.

Maragos, et al (2002)^[61] had conducted a study to compare the effectiveness of three methods using calcium sulfate as a graft/barrier for the treatment of Class II mandibular furcation defects. A total of 36 defects in 17 patients were treated with a graft/barrier of pure calcium sulfate, calcium sulfate plus doxycycline, or demineralized freeze-dried bone allograft (DFDBA) in a 2:1 ratio by volume. The parameters recorded were vertical and horizontal probing depth, defect volume and vertical clinical attachment. Measurement parameters were standardized to a light-cured acrylic resin stent at baseline and 6, 9, and 12 months. The addition of doxycycline or DFDBA to calcium sulfate significantly enhanced the clinical outcome than calcium sulfate alone. The study concluded that the addition of DFDBA was

more effective in the treatment of Class II mandibular furcation defects than doxycycline.

GUIDED TISSUE REGENERATION

With the advent of guided tissue regeneration (GTR) based on the concept given by Melcher, restoration of periodontium is being achieved more predictably. The technique using barrier was introduced by Nyman in 1982, and the term GTR was coined by Gottlow in 1986^[62]. GTR is employed with the use of resorbable and non-resorbable membranes which act as a physical barrier to avoid connective and epithelial tissue down-growth into the defect, thereby favouring the regeneration of periodontal tissues^[25].

The barrier membranes recommended for use in GTR must satisfy the following criteria (Greenstein G, Caton JG 1993)

1. Biocompatibility
2. Cell occlusiveness
3. Space making
4. Tissue integration
5. Clinical manageability

Membranes used for periodontal regeneration can be classified as^[62]

1. Nonresorbable expanded-PolyTetrafluoroethylene(e-PTFE)GoreTex
High density poly tetrafluoroethylene (d-PTFE)
Titanium mesh Titanium reinforced PTFE
2. Resorbable Polymeric (vicryl, atrisor, Epiguide) & collagen derived

Wang HL, O'Neal RB, Thomas CL, et al(1994)^[63]evaluated the efficacy of a type I bovine collagen membrane in the treatment of class II furcation defects. 12 patients each with bilateral mandibular furcation defects having attachment loss>6mm were randomly assigned to either control(flap debridement alone) or test group(flap debridement with collagen membrane). Both test and control group demonstrated significant improvement in clinical and intra-surgical parameters, when compared to presurgery status. A significant improvement of furcation bone repair (horizontal) and defect fill was noted in the collagen membrane treated site as compared to presurgery status. Study suggests the use of collagen membrane have beneficial effects in treatment of class II furcation defects.

Chen CC, Wang HL, Smith F, Glickman GN, Shyr Y, O'Neal RB(1995)^[64]conducted a study to compare the clinical regenerative capacity of collagen membrane with or without Demineralized(DFDBA) in treating periodontal intrabony defects in 10 patients. The defects were randomly assigned to either test (collagen membrane plus DFDBA)or control group(collagen membrane alone). The results of the study indicated that the collagen plus DFDBA and the collagen alone treated groups had significant decrease of PPD, gain of CAL, and defect fill when compared to the presurgery status. Both the groups promoted significant resolution of periodontal intrabony defects. The addition of bone graft with collagen membrane appears to add on extra benefit to collagen membrane treatment.

Paulo M. Camargo, et al(2001)^[65]A controlled re-entry study on the effectiveness of bovine porous bone mineral used in combination with a collagen membrane of porcine origin in the treatment of intrabony defects in humans this study employed a split-mouth design. 22 paired intrabony defects were treated and surgically re-entered

6 months after treatment. Experimental sites were grafted with bovine porous bone mineral and received a collagen membrane for guided tissue regeneration. Control sites were treated with an open flap debridement. The results concluded that clinical resolution of intrabony defects can be achieved using a combination of bovine porous bone mineral and an absorbable, porcine derived collagen membrane.

Nevins ML, Camelo M, Lynch S, Schenk RK, Nevins M (2001)^[66] evaluated the clinical, radiographic and histologic response to the composite use of bone mineral; (BIO-OSS) and the autogenous bone in combination with a bilayer collagen membrane (BIO-GIDE) for the treatment of human periodontal osseous defects. Preoperative and 9 months postoperative recordings included radiographs, clinical probing depths and attachment levels. After 9 months clinical and radiographic recordings were done and histologic sections were taken which on observation revealed new cementum (with inserting collagen fibers) and new bone formation on the surface of both types of graft materials. This human histologic study demonstrated that the autogenous bone in combination with porous bone mineral matrix, and the porcine derived collagen membrane, has the potential to stimulate significant new bone and cementum formation with Sharpey's fiber attachment.

Eickholz P, Kim TS, Dorfer C, Holle R, Hausmann E (2001)^[67] conducted a 5 year study to clinically and radiographically evaluate the long term results after GTR therapy of Class II furcation defects using non resorbable and bio absorbable barriers. 9 pairs of contralateral class II furcation defects were treated in 9 patients with advanced periodontitis. In each patient, one defect received ePTFE (control) and other polyglactin 910 (test) by random assignment. At baseline 6 and 60±3 months after surgery, clinical parameters and radiographs were obtained. Gain of bone density

within furcation areas was assessed using subtraction radiography. Results showed CAL-H gain achieved after GTR therapy in class II furcation was stable after 5 years in 16 of 18 defects. The study failed to show a statistically significant difference in stability of CAL -H gain between control and test groups 5 years after GTR therapy.

Sculean A , Chiantella GC, Windish P, Arweiler NB, Breex M, Gera I(2005)^[68] conducted the study to compare clinically the treatment of deep intra-bony defects with a combination of a composite bovine-derived xenograft(BDX Coll) and a bioresorbable collagen membrane (GTR) to access flap surgery only. Within the limits of this present study, it was concluded that the combination of BDX Coll+GTR resulted in significantly higher CAL gains than treatment with access flap surgery alone, and thus appears to be suitable alternative for treatment intra-bony periodontal defects.

HYALURONIC ACID GEL

HISTORICAL BACKGROUND

Hyaluronic acid was discovered in 1934 by Karl Meyer and his colleague John Palmer, scientists at Columbia University, New York, who isolated a chemical substance from the vitreous jelly of cow's eyes. They proposed the name hyaluronic acid as it was derived from Greek word hyalos (glass) and contained two sugar molecules one of which was uronic acid^[70].

STRUCTURE

Hyaluronic acid (HA) is naturally occurring non sulphated glycosaminoglycan with high molecular weight of 4,000- 20,000,000 daltons. HA structure consists of polyanionic disaccharide units of glucuronic acid and N-acetylglucosamine connected

by alternating 1–3 and 1–4 bonds^[69]. It is a linear polysaccharide of the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchymal cells, vitreous humor, skin and many other organs and tissues of the body. Most cells of the body are capable of synthesizing hyaluronic acid and synthesis takes place in the cell membrane. Hyaluronan binds to many other extracellular matrix molecules, binds specifically to cell bodies through cell surface receptors, and has a unique mode of synthesis in which the molecule is extruded immediately into the extracellular space upon formation. Extensive studies on the chemical and physicochemical properties of HA and its physiological role in humans have proved that it is an ideal biomaterial for cosmetic, medical, and pharmaceutical applications^[70].

In the field of dentistry, preliminary clinical trials have been conducted by Pagnacco and Vangelisti in 1997^[71]. HA has shown anti-inflammatory, anti-edematous, and anti-bacterial effects for the treatment of periodontal disease, which is mainly caused by the microorganisms present in subgingival plaque. It has been found that the equilibrium between the free radicals/reactive oxygen species (ROS) and antioxidants is the major prerequisite for healthy periodontal tissue. Individuals suffering from periodontitis might be at a higher risk of developing other systemic inflammatory diseases like cardiovascular diseases and diabetes.

PROPERTIES^[69,70]

1. Hygroscopic nature

Hyaluronic acid is one of the most hygroscopic molecules known in nature. When HA is incorporated into aqueous solution, hydrogen bonding develops between adjacent carboxyl and N-acetyl groups; this feature allows hyaluronic acid to maintain

conformational stiffness and to retain water. One gram of hyaluronic acid can bind up to 6 L of water. As a physical background material, it has functions in space filling, lubrication, shock absorption, and protein exclusion (Sutherland IW 1998).

2. Viscoelastic properties

The viscoelastic properties of the material may slow the penetration of viruses and bacteria, a feature of particular interest in the treatment of periodontal diseases. Hyaluronan as a viscoelastic substance assists in periodontal regenerative procedures by maintaining spaces and protecting surfaces⁽⁶⁴⁾. Through recognition of its hygroscopic and viscoelastic nature, hyaluronic acid can influence the cell functions that modify the surrounding cellular and extracellular micro and macro environments.

FUNCTIONS

1. Modulation of inflammation

- Enhanced inflammatory cell and extracellular matrix cell infiltration into the wound site
- Elevation in pro-inflammatory cytokine production by inflammatory cells and extracellular matrix cells.
- Organization and stabilization of granulation tissue matrix.
- Scavenges reactive oxygen species, such as superoxide radical ($\cdot\text{O}_2$) and hydroxyl radical ($\cdot\text{OH}$) thus preventing periodontal destruction.
- Inhibition of inflammatory cell-derived serine proteinases (Weigel PH et al., 1988)

2. Stimulation of cell migration, proliferation, and differentiation

The remarkable hydrophilicity of hyaluronic acid makes the coagulum more receptive and thus more likely to undergo colonization by the cells committed to the reconstruction of the damaged tissue by migration, proliferation and differentiation of mesenchymal and basal keratinocytes (Toole BP 2001).

3. Effect on angiogenesis

Deed R et al., 1997 , studied the effect of hyaluronan on angiogenesis and stated that low molecular weight hyaluronic acid has a marked angiogenic effect whereas, surprisingly, high molecular weight has the opposite effect.

4. Osteoconductive potential

Hyaluronic acid accelerates the bone regeneration by means of chemotaxis, proliferation and successive differentiation of mesenchymal cells. Hyaluronic acid shares bone induction characteristics with osteogenic substances such as BMP-2 and osteopontin (Mendes RM et al., 2008).

5. Carrier function

Hyaluronic acid may act as biomaterial scaffold for other molecules, such as BMP-2 and PDGF-BB, used in guided bone regeneration techniques and tissue engineering research (Hunt DR et al., 2001)

6. Bacteriostatic effect

Recent studies on regenerative surgical procedures indicate that reduction of bacterial burden at the wound site may improve the clinical outcome of regenerative therapy.

The high concentration of medium and lower molecular weight hyaluronic acid has the greatest bacteriostatic effect, particularly on *Aggregatibacter actinomycetemcomitans*, *Prevotella oris* and *Staphylococcus aureus* strains commonly found in oral gingival lesions and periodontal wounds (Pirnazar P et al., 1999)

CLINICAL APPLICATIONS IN PERIODONTICS

- Topical application of subgingival hyaluronic acid gel can be used as an adjunct to scaling and root planing.
- Bone regeneration in periodontal bony defects.
- Guided Bone Regeneration.
- In non-surgical therapy of peri-implant pockets.
- Peri-implant maintenance of immediate function implants.
- As autologous cell hyaluronic acid graft gingival augmentation in mucogingival surgery.
- As a carrier for newer molecules in various regenerative procedures.
- As a biomaterial scaffold in tissue engineering research.

CLINICAL STUDIES

Pirnazar P et al., 1999^[71] suggested that the clinical application of hyaluronic membrane, gels or sponges during surgical therapy reduces bacterial contamination of surgical wound site, thereby, lessening the risk of postsurgical infection and promoting more predictable regeneration.

According to **Hunt DR et al., 2001**^[72], hyaluronan is thought to be the best carrier for the Bone Morphogenic Proteins (BMP), the growth factors commonly documented to stimulate the formation of new bone tissue.

Pistorius Alixander et al., 2005^[73], evaluated the efficacy of topical application of HA for treatment of gingivitis and found that topical application of HA containing preparation was potentially useful adjunct in the therapy of gingivitis. Gengigel® (Ricerfarma s.r.l, Milano, Italy) is a topically applied anti-inflammatory product that has been specifically developed for dental use. It contains high molecular weight fractions of hyaluronic acid in gel formulation with 0.2% concentration.

According to **Koshal A et al., 2007^[74]**, the adjunctive use of Gengigel® after thorough mechanical debridement has major clinical benefits in terms of improved healing after non-surgical therapy and demonstrates significant improvements in bleeding on probing and pocket depth measurements.

Vanden Bogaerde L. 2009^[75], treated periodontal intra-bony defects with esterified hyaluronic acid. A full-thickness flap was raised and the roots were accurately planed; hyaluronic acid in the form of fibers was then packed into the defect to completely fill the space. One year after treatment, the mean PPD was reduced by 5.8 mm (range, 0 to 10 mm), gingival recession had increased by 2.0 mm (range, 0 to 6 mm), and attachment gain was 3.8 mm (range, 0 to 7 mm).

Pilloni et al., 2011^[76], in their randomized controlled clinical pilot study, evaluated the efficacy of an esterified form of HA gel on periodontal clinical parameters. The periodontal clinical parameters were plaque index (PI), BOP, PPD, gingival index (GI), and probing attachment level. In the end of the study, they concluded that an esterified gel form of HA has shown an effect in reducing the gingival inflammation when used as an adjunct to mechanical home plaque control and that it could be successfully used to improve the periodontal clinical indexes.

Fawzy El-Sayed et al., 2012^[77], in a randomized controlled trial evaluated the effect of local application of 0.8% Hyaluronan gel in conjunction with periodontal surgery and noted statistically significant differences in clinical attachment level ($P < 0.05$) in favor of the test sites though non-significant results were obtained regarding probing depth.

Sandhu GK et al., 2015^[80] reported the regenerative capacity of HA gel (Gengigel®) in conjunction with PRF in a patient with Grade II furcation defect, through surgical re-entry after 6 months. The furcation area was reassessed clinically with the help of Q2N Naber's probe to assess the bone fill. Healing was uneventful and at 6 months of follow-up, there was substantial defect fill in the furcation area with a residual horizontal dimension of <1 mm at 6 months, representing a significant percentage of bone formation. Hence it was observed that the combined approach resulted in significant furcation defect fill on re-evaluation at 6 months.

Kalra et al., in 2015^[81] reported the radiographic assessment of the regenerative capacity of HA gel (Gengigel®) in conjunction with bioactive amnion GTR membrane in a patient with Grade II furcation defect. Roentgenographic assessment was done at 4 months and 6 months postoperatively. It resulted in complete defect fill and loss of radiolucency at 6 months. The authors stated that the surgical placement of HA gel along with amnion membrane in the furcation defect can significantly improve the periodontal defect morphology.

Sugandha Gupta et al., 2017^[82], evaluated the role of Gengigel® (0.8% hyaluronic acid) as a potential material for regeneration of lost attachment apparatus. A total of 20 sites with Grade II furcation defects from 10 patients were selected using random

sampling technique. These were divided into Group A (placement of hyaluronic acid) and Group B (without placement of hyaluronic acid) according to treatment modality. Furcation defect assessment was done in vertical and horizontal depth preoperatively and postoperatively at six months through surgical re-entry. The results showed that mean plaque index, gingival index and bleeding index score were statistically significant for both the groups at baseline and six months. Mean difference in probing pocket depth and Relative Attachment Level (RAL) were statistically highly significant, whereas, mean difference of gingival position margin was not significant for both the groups, at baseline and six months. Mean difference in horizontal component at baseline and six months was statistically highly significant for both the groups. Mean difference in vertical component at baseline and six months was statistically significant for both the groups. On comparison, the mean difference in vertical and horizontal component of Group A and Group B at six months was statistically not significant. It was concluded that both Gengigel® with coronally positioned flap and coronally positioned flap alone were effective in the treatment of Grade II furcation defects. The combination of Gengigel® with coronally positioned flap leads to better results in hard tissue measurement as compared to coronally positioned flap alone.

MATERIALS AND METHODS

SOURCE OF DATA:

The study was conducted in the Department of Periodontics, KAHER's KLE V.K. Institute of Dental Sciences, Belagavi. It was a randomized controlled clinical trial which was carried out over a period of 6 months. An ethical clearance (Annexure I) was obtained before conducting the study from the Ethical Committee, KAHER's KLE V.K. Institute of Dental Sciences, Belagavi.

The sample size was calculated by using the following formula:

$$N_{\text{pairs}} = \frac{2(s^2)}{d^2} (Z_{1-\alpha/2} + Z_{1-\beta})^2$$

Where,

$$S = S_2 - S_1 = 1.05 - 0.72 = 0.33$$

$$Z = 1.96$$

$$Z = 0.842$$

$$d = 0.9765$$

$$\text{Power}(\%) = 85$$

$$\text{Error}(\%) = 5$$

$$\text{error}(\%) = 20$$

Thus, a total of 13 patients with a total of 26 sites having bilateral Grade II furcation involvement, reporting to the outpatient unit, Department of Periodontics, KAHER's KLE V.K. Institute of Dental Sciences, Belagavi were selected for the study.

Informed consent (Annexure II) was taken from all the subjects after explanation of the nature, risks and benefits of the clinical procedure.

Patients who met the following criteria were included in the study:

INCLUSION CRITERIA:

- A total of 26 mandibular molars with grade II furcation involvement (buccal or lingual) according to Hamp et al classification of furcation (1975), Naber's probe marking 3-4mm.
- Patients aged between 25-60 years .
- Pocket probing depth of 5mm.
- Patients with no medical history.
- Patient who have not received any type of periodontal therapy in the past 6months.

EXCLUSION CRITERIA:

- Systemic conditions affecting bone density e.g. osteoporosis, Paget's disease.
- Use of anticoagulants and immunosuppressive agents or any other drugs that interfere with the healing process.
- History of drug intake in the past 6 months that can affect bone metabolism.
- Pregnant or lactating women.
- Patients who have undergone any periodontal treatment or received antibiotic therapy in the last 3 months.

STUDY DESIGN

13 subjects with 26 sites of mandibular bilateral Grade II furcations were selected. A thorough phase I therapy (supragingival and subgingival scaling) was done for all the subjects. Subjects were recalled after three weeks for regenerative procedure. Laboratory investigations such hemoglobin level, bleeding time and clotting time, random blood sugar level were assessed prior to the surgery. Pre-operative photographs were taken.

They were divided into 2 groups by lottery method of randomization. The groups were as follows:

- Group A –Grade II furcation defects treated with Demineralized Freeze Dried Bone Allograft (DFDBA) and Guided Tissue Regenerative Membrane(HEALIGUIDE®)
- Group B - Grade II furcation defects treated with 0.8% GENGIGEL® and Guided Tissue Regenerative Membrane (HEALIGUIDE®)

A proforma (Annexure III) was designed for the study to enable methodological recording of all the observations and information. The relevant data comprising of personal details of the patient, chief complaint, past dental history were recorded before starting the surgical procedure.

OCCLUSAL STENT FABRICATION:

Customized acrylic stent using cold-cure acrylic resins will be prepared on the stone models by taking alginate impression of the patients. Extent of the Stent will be on one adjacent tooth in the mesial and distal direction and will cover the coronal third of tooth crowns. Vertical groove will be made in relation to the involved tooth,

which will guide the probe while recording the measurements. This technique provides a fixed reference point(FRP) and fixed angulations for measurements of parameters pre operatively as well as post operatively. All the customized acrylic stents should be stored on the prepared study cast throughout the study period to minimize distortion.

The following clinical parameters were measured with the aid of a William's graduated periodontal probe in millimetres:

- Probing Pocket Depth (PPD): It was measured from gingival margin to base of the sulcus.
- Sulcus Bleeding index (BI) :It is developed by MUHLEMANN H.R and SON.S in 1971.The purpose of this index is to locate areas of gingival sulcus bleeding upon gentle probing.
- Relative Attachment Level (RAL): It is measured from the fixed reference point(occlusal stent) to the base of the pocket.

Along with the previous mentioned clinical parameters, the radiographic parameters weremeasured at baseline, 1 month and 6 months after surgery.

The horizontal component of the furcation was evaluated using a Nabers probe and the vertical component is measured on a radiograph. The radiographic assessment was done using RADIOVISIOGRAPHY with grid in position.

CLINICAL ARMAMENTARIUM

1. Surgical drape
2. Disposable head cap
3. Disposable Mouth mask
4. Disposable gloves
5. Cotton swabs and gauze
6. 2% Lignocaine HCl containing 1:80,000 adrenaline with sterile and disposable syringe
7. Kidney tray
8. Mouth mirror
9. Straight probe
10. Tweezers
11. Explorer
12. William's periodontal probe
13. Nabers probe
14. Bard Parker handle with 11,12,15
15. Molts Periosteal Elevator
16. Gracey curettes
17. Castroviejo scissors
18. Adson tissue holding forceps
19. Needle holder
20. Saline with sterile and disposable irrigating syringes
21. Dappen dish
22. DFDBA(Tata Tissue Bank, Mumbai, Maharashtra) as graft material
23. Syringe loaded with GENGIGEL[®] (RICERFARMA ,Milano, ITALY)

24. Collagen membrane (HEALIGUIDE[®])
25. Suture material - 4-0 Vicrylresorbable suture (Ethicon, Jhonson and Jhonson PVT Ltd.)
26. Black braided silk suture.
27. Periodontal pack (Coe Pak[™],GC America Inc, USA)

SURGICAL TECHNIQUE

GROUP A

Demineralized Freeze Dried Bone Allograft (DFDBA) +Guided Tissue Regenerative Collagen Membrane

- The operative site was local anaesthetised (2% Lignocaine HCl with 1:80,000 Adrenaline),.
- Horizontal incisions were given using a no.15 blade and a full thickness mucoperiosteal flap was reflected using a periosteal elevator.
- The granulation tissue was debrided and root planning was performed using Gracey curettes.
- Required quantity of DFDBA was transferred into a Dappen dish and mixed with saline.
- Small increments of the material was placed at the defect site, condensed and completely filled followed by placement of GTR collagen membrane (HEALIGUIDE®)
- The collagen membrane was stabilized with 4-0 Vicrylresorbable suture(Ethicon, Jhonson and Jhonson PVT Ltd.)
- Following this, the mucoperiosteal flap was repositioned and interrupted sutures were placed using silk suture(3-0)
- After which periodontal dressing (Coe Pak™) was given.

GROUP B

Gengigel[®]+Guided Tissue Regenerative Collagen Membrane

- Adequate quantity of local anaesthesia was administered (2% Lignocaine HCl with 1:80,000 Adrenaline).
- Using a no.15 blade horizontal incisions were given and a full thickness mucoperiosteal flap was reflected using a Molts no 9 periosteal elevator.
- Debridement and root planning was performed using Gracey curettes.
- Required quantity of 0.8% Gengigel[®] was taken in a disposable syringe and placed at the defect site.
- Following this, the GTR collagen membrane (HEALIGUIDE[®]) was placed and stabilized with 4-0 Vicryl resorbable suture (Ethicon, Johnson and Johnson PVT Ltd.)
- The mucoperiosteal flap was then repositioned and interrupted sutures were placed using silk suture (3-0).
- After which periodontal dressing (Coe Pak[™]) was placed over the surgical site.

The post-operative pharmacological regime included antibiotics (combination of Amoxicillin 500 mg and Clavulanic acid 125 mg twice daily for 5 days) & analgesics (Ketorolac 10 mg twice daily for 3 days) along with betadine mouth rinse.

Following post-operative instructions were given to the patients

- 1) Avoid spitting and rinsing for first 24 hrs after the surgery.
- 2) Avoid brushing vigorously in the operated area.
- 3) Avoid touching the operated area with tongue or finger.
- 4) Consume semi-solid or liquid diet for first 24 hrs after the surgery.
- 5) Apply ice intermittently on the face over the operated area on the day of the surgery.
- 6) Avoid too hot or spicy food.
- 7) In case of any excessive bleeding, report to the clinician as soon as possible.
- 8) Rinse with 10ml of 0.2% chlorhexidine mouth rinse twice daily for 7 days.
- 9) Take the medication as prescribed by the dentist.

All the patients were recalled for suture removal after 7 days of the surgery. Clinical parameters were recorded for all patients at a follow-up of 1 month, 3 months and 6 months subsequently.

FIG 1: ARMAMENTARIUM



FIG 2: MATERIALS USED FOR THE STUDY



FIG 3: GROUP A (DFDBA+GTR)



Pre-operative Evaluation of Grade II furcation Using Nabers Probe



Measuring Probing Depth Using Pre-Fabricated Stent



RVG at baseline



Mucoperiosteal Flap Elevation



Placement of Bone Graft (DFDBA)



Collagen membrane placed and sutured



Flap approximated and sutured




Post Operative 1 Month follow- up
CLINICAL AND RADIOGRAPHIC ASSESSMENT




Post Operative 6 Month follow up
CLINICAL AND RADIOGRAPHIC ASSESSMENT

FIG 4: GROUP B (GENGIGEL +GTR)



Pre- Operative Measurements At Baseline



RVG At Baseline



Mucoperiosteal flap elevation




Placement of Gengigel




Collagen Membrane Placed and Sutured



Suturing Done



Post – Op 1 Month follow up (Clinical and Radiographic Photographs)



Post – Op 6month Follow Up (Clinical and Radiographic Photographs)

RESULTS AND OBSERVATIONS

A total of 13 patients with mandibular Grade II furcation defects were treated with either DFDBA and guided tissue regeneration (DFDBA + GTR) (Group A) or 0.8% GENGIGEL and guided tissue regeneration (0.8% GENGIGEL + GTR) (Group B). All the patients were recalled at 1 month and 6 months for follow-up out of which 3 patients could not report for follow up and hence were considered drop outs due the current situation of covid-19. Therefore, the statistical analysis was carried out for 10 patients who reported at subsequent follow-ups.

The data was entered in Microsoft excel and subjected to statistical analysis using SPSS software version 20.0.

Baseline data for both the groups was almost the same as the study was carried out with a split mouth design. Of the 10 patients, 6 were females and 4 were males with a mean age of 37.93 ± 6.02 . (Table 1 and Table 2).

The scores of variables – Sulcus Bleeding Index (SBI), Probing Pocket Depth (PPD), Relative Attachment Level (RAL), Horizontal Furcation Involvement, Vertical Furcation Involvement at different time points in Group A and Group B were recorded. Independent t- test was applied for intergroup comparison between Group A and Group B and Kolmogorov Smirnov test was applied for intra group comparison.

Table 1 : Gender wise distribution.

Gender	Number	Percent
Male	4	40.00
Female	6	60.00
Total	10	100.00

Table 2: Comparison of Group A and Group B with mean age by Independent t-test

Groups	Mean	SD	SE	t-value	P-value
Group A	37.93	6.02	1.12	0.0000	1.0000
Group B	37.93	6.02	1.12		

Table 3 :Comparison of Group A and Group B with Sulcus Bleeding Index at baseline, 1month and 6months time points by Independent t-test.

Time points	Group A		Group B		t-value	p-value
	Mean	SD	Mean	SD		
Baseline	1.84	0.37	1.72	0.33	0.7660	0.4536
1 month	1.29	0.37	1.27	0.31	0.1046	0.9179
6 months	0.89	0.20	0.86	0.19	0.3493	0.7309
BL-1M	0.55	0.38	0.45	0.35	0.6389	0.5309
BL-6M	0.96	0.40	0.87	0.37	0.5215	0.6084
1M-6M	0.40	0.26	0.42	0.26	-0.1209	0.9051


SD- Standard Deviation

Table 4 : Comparison at baseline , 1month and 6months time points with Sulcus Bleeding Index in Group A and Group B by Kolmogorov Smirnov


Groups	Time points	Mean	SD	Mean Diff.	SD Diff.	% of change	Paired t	P-value
Group A	Baseline	1.84	0.37					
	1month	1.29	0.37	0.55	0.38	30.04	4.6403	0.0012*
	Baseline	1.84	0.37					
	6 months	0.89	0.20	0.96	0.40	51.95	7.6055	0.0001*
	1 month	1.29	0.37					
	6 months	0.89	0.20	0.40	0.26	31.32	4.9744	0.0008*
Group B	Baseline	1.72	0.33					
	1month	1.27	0.31	0.45	0.35	26.10	4.0667	0.0028*
	Baseline	1.72	0.33					
	6 months	0.86	0.19	0.87	0.37	50.35	7.3577	0.0001*
	1 month	1.27	0.31					
	6 months	0.86	0.19	0.42	0.26	32.81	5.0617	0.0007*

*p<0.05, MD- Mean Difference, SD- Standard Deviation.

Graph 1: Gender wise distribution



Graph 2: Comparison of group A and group B with relative attachment level (mm) at baseline, 1 month and 6 months time points



SULCUS BLEEDING INDEX(SBI) (Table 3,4; Graph 1,2)

The mean sulcus bleeding index at baseline for control group was 1.84 with S.D \pm 0.37, whereas values at 1 month was 1.29 ± 0.37 and 0.89 ± 0.20 at 6 months. The mean sulcus bleeding index when compared from baseline to 6 months was 0.96 ± 0.40 which was statistically significant.

The mean sulcus bleeding index at baseline for experimental group was 1.72 with S.D \pm 0.33, whereas values at 1 month was 1.27 ± 0.31 and 0.86 ± 0.19 at 6 months. The mean sulcus bleeding index when compared from baseline to 6 months was 0.87 ± 0.37 which was statistically significant.

The mean sulcus bleeding depth when compared between the control and experimental groups at 6 months post surgery was 0.03, which was not statistically significant. The comparison showed no much difference between the experimental group and the control group.

Table 5: Comparison of group A and group B with Probing Pocket Depth at baseline , 1month and 6months time points by Independent t test.



Time points	Group A		Group B		t-value	p-value
	Mean	SD	Mean	SD		
Baseline	7.00	0.94	7.20	0.79	-0.5145	0.6132
1 month	5.50	1.08	6.00	0.94	-1.1028	0.2846
6 months	2.50	1.08	2.40	0.84	0.2308	0.8201
BL-1M	1.50	0.53	1.20	0.79	1.0000	0.3306
BL-6M	4.50	1.18	4.80	1.32	-0.5369	0.5979
1M-6M	3.00	1.25	3.60	1.07	-1.1523	0.2643

MD- Mean Difference, SD- Standard Deviation.

Table 6 : Comparison of baseline, 1 month and 6months time points with Probing Pocket Depth in Group A and Group B by Kolmogorov Smirnov

Groups	Time points	Mean	SD	Mean Diff.	SD Diff.	% of change	Paired t	P-value
Group A	Baseline	7.00	0.94					
	1month	5.50	1.08	1.50	0.53	21.43	9.0000	0.0001*
	Baseline	7.00	0.94					
	6 months	2.50	1.08	4.50	1.18	64.29	12.0748	0.0001*
	1 month	5.50	1.08					
	6 months	2.50	1.08	3.00	1.25	54.55	7.6064	0.0001*
Group B	Baseline	7.20	0.79					
	1month	6.00	0.94	1.20	0.79	16.67	4.8107	0.0001*
	Baseline	7.20	0.79					
	6 months	2.40	0.84	4.80	1.32	66.67	11.5292	0.0001*
	1 month	6.00	0.94					
	6 months	2.40	0.84	3.60	1.07	60.00	10.5903	0.0001*

*p<0.05, MD- Mean Difference, SD- Standard Deviation.



PROBING POCKET DEPTH (Table 5,6; Graph 3,4)

The main pocket depth at baseline was 7.00mm with S.D \pm 0.94 for the control group, whereas values at 1 month were 5.50 ± 1.08 and 2.50 ± 1.08 at 6 months post surgery. The mean pocket depth reduction when compared from baseline to 6 months was 4.50 ± 1.18 which was statistically significant.

The main pocket depth at baseline was 7.20mm with S.D \pm 0.79 for the experimental group, whereas values at 1 month were 6.00 ± 0.94 and 2.40 ± 0.84 at 6 months post surgery. The mean pocket depth reduction when compared from baseline to 6 months was 4.80 ± 1.32 which was statistically significant.

The mean pocket depth reduction when compared between the experimental and control group at 6 months post surgery was 0.5mm which was not statistically significant. The comparison showed pocket depth reduction for the control group as compared to experimental group.

Table 7 : Comparison of Group A and Group B with Relative Attachment Level at baseline , 1month and 6months time points by Independent t test.



Time points	Group A		Group B		t-value	p-value
	Mean	SD	Mean	SD		
Baseline	8.60	1.43	8.40	1.35	0.3216	0.7514
1 month	7.10	0.99	7.00	1.25	0.1982	0.8451
6 months	5.60	0.97	5.90	1.29	-0.5896	0.5628
BL-1M	1.50	0.97	1.40	0.70	0.2641	0.7947
BL-6M	3.00	1.15	2.50	0.71	1.1677	0.2581
1M-6M	1.50	0.85	1.10	0.57	1.2377	0.2317

SD- Standard Deviation.

Table 8 : Comparison of baseline, 1month and 6months time points with Relative Attachment Level in Group A and Group B Kolmogorov Smirnov

Groups	Time points	Mean	SD	MD	SD Diff.	% of change	Paired t	P-value
Group A	Baseline	8.60	1.43					
	1month	7.10	0.99	1.50	0.97	17.44	4.8809	0.0009*
	Baseline	8.60	1.43					
	6 months	5.60	0.97	3.00	1.15	34.88	8.2158	0.0001*
	1 month	7.10	0.99					
	6 months	5.60	0.97	1.50	0.85	21.13	5.5816	0.0003*
Group B	Baseline	8.40	1.35					
	1month	7.00	1.25	1.40	0.70	16.67	6.3317	0.0001*
	Baseline	8.40	1.35					
	6 months	5.90	1.29	2.50	0.71	29.76	11.1803	0.0001*
	1 month	7.00	1.25					
	6 months	5.90	1.29	1.10	0.57	15.71	6.1279	0.0002*

*p<0.05, MD- Mean Difference, SD- Standard Deviation.



RELATIVE ATTACHMENT LEVEL (Table 7,8; Graph 5,6)

The mean relative attachment level at baseline for control group was 8.60mm with S.D \pm 1.43, whereas value at 1month was 7.10 ± 0.99 and 5.60 ± 0.97 at 6 months post surgery. The mean relative attachment level when compared from baseline to 6 months was 3.00 ± 1.15 which was statistically significant.

The mean relative attachment level at baseline for experimental group was 8.40mm with S.D \pm 1.35, whereas value at 1 month was 7.00 ± 1.25 and 5.90 ± 1.29 at 6 months post surgery. The mean relative attachment level when compared from baseline to 6 months was 2.50 ± 0.71 which was statistically significant.

The mean relative attachment level when compared between the experimental and control group at 6 months post surgery was 0.3mm, which was not statistically significant. The comparison showed higher relative attachment level gain for the experimental group as compared to control group.

Table 9 :Comparison of Group A and Group B with Horizontal Furcation Involvement at baseline, 1month and 6months time points by Independent t- test



Time points	Group A		Group B		t-value	p-value
	Mean	SD	Mean	SD		
Baseline	4.20	0.63	4.30	0.67	-0.3419	0.7364
1 month	3.90	0.74	4.10	0.74	-0.6061	0.5520
6 months	1.50	0.85	1.30	0.95	0.4966	0.6255
BL-1M	0.30	0.48	0.20	0.42	0.4932	0.6278
BL-6M	2.70	0.67	3.00	0.94	-0.8182	0.4240
1M-6M	2.40	0.52	2.80	1.03	-1.0954	0.2878

SD- Standard Deviation.

Table 10: Comparison of baseline, 1month and 6months time points with Horizontal Furcation Involvement in Group A and Group B by Kolmogorov Smirnov

Groups	Time points	Mean	SD	Mean Diff.	SD Diff.	% of change	Paired t	P-value
Group A	Baseline	4.20	0.63					
	1month	3.90	0.74	0.30	0.48	7.14	1.9640	0.0811
	Baseline	4.20	0.63					
	6 months	1.50	0.85	2.70	0.67	64.29	12.6501	0.0001*
	1 month	3.90	0.74					
	6 months	1.50	0.85	2.40	0.52	61.54	14.6969	0.0001*
Group B	Baseline	4.30	0.67					
	1month	4.10	0.74	0.20	0.42	4.65	1.5000	0.1679
	Baseline	4.30	0.67					
	6 months	1.30	0.95	3.00	0.94	69.77	10.0623	0.0001*
	1 month	4.10	0.74					
	6 months	1.30	0.95	2.80	1.03	68.29	8.5732	0.0001*

*p<0.05, MD- Mean Difference, SD- Standard Deviation.



HORIZONTAL FURCATION INVOLVEMENT (Table 9,10; Graph 7,8)

The mean horizontal furcation involvement at baseline for control group was 4.20mm with S.D \pm 0.63mm, whereas values at 1 month was 3.90 ± 0.74 mm and 1.50 ± 0.85 at 6 months post surgery. The mean horizontal furcation involvement at baseline to 6 months was 2.70 ± 0.67 mm which was statistically significant.

The mean horizontal furcation involvement at baseline for experimental group was 4.30mm with S.D \pm 0.67mm, whereas values at 1 month was 4.40 ± 0.74 mm and 1.30 ± 0.95 at 6 months post surgery. The mean horizontal furcation involvement at baseline to 6 months was 3.00 ± 0.94 mm which was statistically significant.

The mean horizontal furcation involvement when compared between the control and experimental group at 6 months post surgery was 0.2mm which was not statistically significant. The comparison showed reduction in the mean horizontal furcation involvement for the experimental group as compared to control group.

Table 11 :Comparison of Group A and Group B with Vertical Furcation Involvement at baseline , 1month and 6months time points by Independent t-test.



Time points	Group A		Group B		t-value	p-value
	Mean	SD	Mean	SD		
Baseline	5.05	0.69	5.00	0.58	0.1765	0.8619
1 month	5.05	0.69	5.00	0.58	0.1765	0.8619
6 months	3.60	0.77	3.50	0.71	0.3015	0.7665
BL-1M	0.00	0.00	0.00	0.00	--	--
BL-6M	1.45	0.86	1.50	0.58	-0.1521	0.8808
1M-6M	1.45	0.86	1.50	0.58	-0.1521	0.8808

SD- Standard Deviation.

Table 12 : Comparison of baseline, 1month and 6months time points with Vertical Furcation Involvement in Group A and Group B Kolmogorov Smirnov

Groups	Time points	Mean	SD	Mean Diff.	SD Diff.	% of change	Paired t	P-value
Group A	Baseline	5.05	0.69					
	1month	5.05	0.69	0.00	--	0.00	--	--
	Baseline	5.05	0.69					
	6 months	3.60	0.77	1.45	0.86	28.71	5.3045	0.0005*
	1 month	5.05	0.69					
	6 months	3.60	0.77	1.45	0.86	28.71	5.3045	0.0005*
Group B	Baseline	5.00	0.58					
	1month	5.00	0.58	0.00	--	0.00	--	--
	Baseline	5.00	0.58					
	6 months	3.50	0.71	1.50	0.58	30.00	8.2158	0.0001*
	1 month	5.00	0.58					
	6 months	3.50	0.71	1.50	0.58	30.00	8.2158	0.0001*

*p<0.05, MD- Mean Difference, SD- Standard Deviation.



VERTICAL FURCATION INVOLVEMENT (Table 11,12; Graph 9,10)

The mean vertical furcation involvement at baseline for control group was 5.05mm with S.D \pm 0.69mm, whereas values at 1 month was 5.05 ± 0.69 mm and 3.60 ± 0.77 at 6 months post surgery. The mean horizontal furcation involvement at baseline to 6 months was 1.45 ± 0.86 mm which was statistically significant.

The mean vertical furcation involvement at baseline for experimental group was 5.00mm with S.D \pm 0.58mm, whereas values at 1 month was 5.00 ± 0.58 mm and 3.50 ± 0.71 at 6 months post surgery. The mean horizontal furcation involvement at baseline to 6 months was 1.50 ± 0.58 mm which was statistically significant.

The mean vertical furcation involvement when compared between the control and experimental group at 6 months post surgery was 0.1mm which was not statistically significant. The comparison showed reduction in the mean vertical furcation involvement for the experimental group as compared to control group.

The percentage of bone fill in Group A from baseline to 1month was statistically not significant as there is no change in the amount of bone fill that has been observed at the end of 1month and 30 % (1.50 ± 0.58) of bone fill was observed at the end of 6months.

Similarly, in Group B there was no change that has been observed at the end of 1month but on comparison from baseline to 6months about 29% (1.45 ± 0.86) of bone fill was observed.

On intergroup comparison, 1% of difference in bone fill was observed between the groups treated with DFDBA and Gengigel which was not statistically significant.

DISCUSSION

The primary objective of the periodontal treatment is that “it helps in the maintenance of the natural dentition in good health and comfortable function”^[3,4]. When there is an attachment loss due to periodontal disease the optimal care is necessary to regenerate the periodontium to its state that has been present before the disease has occurred. Regeneration has been defined as “The reproduction or reconstruction of a lost or injured part to restore the architecture and function of the periodontium”(AAP Definition)^[5]

A material or a technique which has to be considered as a regenerative modality is that it should demonstrate histologically the formation of cementum, alveolar bone and periodontal ligament on a diseased root. Different bone grafts and also their substitutes have been used to regenerate the lost structures. Use of bone grafts for this purpose i.e. the regenerating the osseous defects produced by periodontal disease in 1923 by Hegedus and was reviewed by Nabers and O’Leary in 1965^[83]. Ever since that period of time a various number of techniques and materials have been employed for regeneration.

Complete regeneration of the functional attachment apparatus has remained an elusive goal of the periodontal therapy, and currently the major progress is being made to achieve this end by utilizing various regenerative procedures such as bone grafting, GTR techniques and combination therapy^[84]. Both animal and human studies have shown that the combination of GTR procedure and bone grafting greatly enhances the regenerative outcome.

The wide spread use of “DFDBA was based on the osteoinductive ability of bone graft preparation” given by Reddi, Urist. When the graft becomes demineralized it exposes the bone inductive proteins that are present in the bone matrix. DFDBA when tested histologically, have shown to be more effective in inducing the periodontal regeneration^[39,45].

Hyaluronic acid, an integral part of the extracellular matrix, has been advocated for periodontal regeneration and healing. Hyaluronan interacts with fibrin clot and provides a structural framework to enable ECM cell infiltration into the inflamed site^[72]. It helps in organisation of granulation tissue by promoting proliferation and migration of matrix cells. Hakansson et al, suggested the role of hyaluronan in migration and adherence of neutrophils and macrophages at the inflamed site and the resultant phagocytosis and destruction of invading pathogens. They also promote angiogenesis and enhance bone formation by their osteoconductiveness^[85].

The use of type I collagen for GTR has an added advantage because, it is uniquely involved in the binding of cells, particularly fibroblasts and osteoblasts, thus promoting periodontal regeneration.

The collagen (type I) was selected as a GTR membrane in the present study was based on the following facts^[86].

1. Type I collagen is the main constituent of periodontal connective tissue and therefore would seem to be an appropriate barrier in the GTR technique.

2. It is bio-absorbable so can act as a barrier analogous to a non resorbable membrane and it is either incorporated into the healing connective tissues or is degraded by macrophages in 6-8 weeks.
3. Exogenous collagen is chemotactic for periodontal ligament fibroblasts and improves fibroblast migration and attachment through its scaffold-like fibrillar structure.
4. It also creates a thrombogenic surface that stimulates platelet attachment which may accelerate fibrin and clot attachment.
5. Collagen is a hemostatic, a property that enhances wound healing.

Thus, the present study aimed to compare and evaluate the use of Demineralized Freeze Dried Bone Allograft(DFDBA) and Gengigel® (0.8%) along with a Guided Tissue Regenerative Membrane(GTR) for the treatment of Grade II furcation defects associated with mandibular posterior teeth.

The study was carried in a split mouth design with Group A- Demineralized Freeze Dried Bone Allograft (DFDBA) and Guided Tissue Regenerative Membrane (HEALIGUIDE®) or Group B- receiving 0.8% GENGIGEL® and Guided Tissue Regenerative Membrane (HEALIGUIDE®).

The clinical parameters were evaluated at baseline, 1 month and 6 month post-operative intervals.

The mean age of the study population was 37.93 ± 6.02 years with 6 females and 4 males.

The parameters recorded were Sulcus Bleeding Index (SBI), Probing Pocket Depth (PPD), Relative Attachment Level(RAL). Horizontal Furcation Involvement

and radiographic evaluation of Vertical Furcation Involvement using RVG at baseline, 1 and 6 month intervals post surgery to evaluate the amount of bone fill.

In 1971, Muhlemann & Sons^[87] had stressed that bleeding was a much more sensitive indicator of disease. It is done by gentle probing along all the surfaces of the tooth. Bleeding on probing is the objective sign of any periodontal disease and is known to be associated with the active disease.

The mean range of Sulcus Bleeding Index (Table 3.1, table 3.2, Graph 1,2) in our study was 1.72 ± 0.37 . The surgical sites showed signs of bleeding on probing and change in color.

The mean values were similar between Group A (1.84 ± 0.37) and Group B (1.72 ± 0.33) at baseline and the differences were not statistically significant ($p=0.45$). Therefore the two groups were comparable at baseline.

In the present study, a gradual decrease in the Sulcus Bleeding Index was observed in both the groups from baseline to 1 month, 1 month to 6 months. The reduction in SBI may be attributed to the decrease in magnitude of the bacteria present in plaque control regime. The reduction in both the cases may be attributed to the resolution of the inflammatory component consequent to access flap surgery and mechanical, chemical plaque control regime.

The fact that collagen membrane helps in creating and maintaining a blood clot-filled space it also prevents inflammation as a result of decreased bacterial invasion^[87] thus resulting in the lower SBI score. The result of our study was comparable to the study conducted by Lekovic(2003), Jepsen(2010) who showed a

decrease in SBI of 0.92 ± 0.25 , 0.89 ± 0.23 respectively from baseline to 6months at the end of the study.

The high concentration of medium and lower molecular weight hyaluronic acid has the greatest bacteriostatic effect, particularly on *Aggregatibacter actinomycetemcomitans*, *Prevotella oris* and *Staphylococcus aureus* strains commonly found in oral gingival lesions and periodontal wounds(85). Koshal A et al., 2007^[87] from his study concluded that the adjunctive use of Gengigel® after thorough mechanical debridement has major clinical benefits in terms of improved healing after non-surgical therapy and demonstrates significant improvements in bleeding on probing. Hyaluronan(Gengigel®) is involved in the activation of inflammatory cells such as PMNs and macrophages, including their migration to wound site and killing the invading microbial pathogens. Pirnazar P et al. , 2011^[88] suggested that the clinical application of hyaluronic membrane, gels or sponges during surgical therapy reduces bacterial contamination of surgical wound site, thereby, lessening the risk of postsurgical infection and promoting more predictable regeneration.

Similarly, a decrease in SBI score was observed by Pistorius Alixander et al., 2005 and Pilloni et al., 2011^[89] of about 0.91 ± 0.20 , 0.85 ± 0.32 respectively at the end of 6months which were almost similar to our present study.

Periodontal pocket is a “pathologically deepened gingival sulcus and is one of the important clinical features of periodontal disease”. It is a soft tissue change that indicates an on-going inflammatory process in the gingival sulcus. The probing depth of a clinically healthy gingival sulcus is 2-3mm. The mean range of Probing Pocket

Depths (Table 4.1, table 4.2 , Graph 3,4) in our study was more than 7 mm. Thus, it could be extrapolated that the surgical sites were inflammatory.

The mean values were similar between Group A (7.00 ± 0.94) and Group B (7.20 ± 0.79) at baseline and the differences were not statistically significant ($p=0.61$). Therefore the two groups were comparable at baseline. A statistically significant decrease in PPD was seen from 5.50 ± 1.08 mm (1month) to 2.50 ± 1.08 mm (6 month) in group A and from 6.00 ± 0.94 mm (1 month) to 2.40 ± 0.84 mm (6 month) in Group B.

During the repair of the surgical site after flap surgery , the granulation tissue derived primarily from contiguous exposed areas of the periodontal ligament expands by proliferation onto treated root surface. It may well serve as the progenitor of the “periodontal attachment”.

Use of collagen membrane as barrier had also improved properties to retard the apical migration of epithelial cells from contacting the space and facilitates repopulation of the defect by regenerative cells ^[85] It also provides an additional wound coverage acting as a duplicate surgical flap to provide added stability and protection of the blood clot and preventing ruptures along the interface between the healing tissues and the root surface, thus promoting better wound healing^[87]

Our results tally with the study conducted by Lovelace et al (1998), Froum et al (2003) and Deepa et al (2015)^[85,87,90] where significant change in PPD at the end of 6 months was observed and has been attributed to the fact that tissue consistency changed throughout the study period.

In the study done by ChhayaBansal et al (2013) had shown similar results where there was reduction in PPD at the end of 9 months. He had concluded that the amount of BMP released and the particle size of DFDBA(200-500 microns) had contributed to its superior results in terms of Probing Pocket Depth.

Similarly, Toole BP 2001^[91] conducted a study where he had explained the remarkable hydrophilicity of hyaluronic acid which makes the coagulum more receptive and thus more likely to undergo colonization by the cells committed to the reconstruction of the damaged tissue by migration, proliferation and differentiation of mesenchymal and basal keratinocytes.

A decrease in PPD was observed in a study conducted by Sadhu et al(2009)^[80] 0.08 ± 0.39 mm ($p=0.25$) for Group A and 0.01 ± 0.59 mm ($p=0.10$) for Group B was seen. A PPD of 3.00 ± 1.25 mm for Group A and 3.60 ± 1.07 mm for group B was observed at the end of 6 months. Therefore, a reduction of probing pocket depth was observed in both the groups.

Relative Attachment Level (RAL) was measured from a fixed reference point (prefabricated stent) to the base of the pocket. The mean scores for relative attachment level Table 5.1, table 5.2 , Graph 5,6) were similar between Group A (8.60 ± 1.43 mm) and Group B (8.40 ± 1.35 mm) and the differences were not statistically significant ($p=0.75$). Therefore the two groups were comparable at baseline. A statistically significant decrease was seen in the mean RAL from 8.60 ± 1.43 mm (baseline) to 7.10 ± 0.99 mm (1 month) to 6.00 ± 0.94 (6 months) 2.40 ± 0.84 in group A and from 8.40 ± 1.35 mm (baseline) to 7.00 ± 1.25 mm (1 month) to 2.40 ± 0.84 mm (6months) in Group B.

However, both the groups showed significant gain in relative attachment level on intragroup comparison from baseline to 1month and 1month to 6months.

Changes in the Relative Attachment Level may be attributed to the reduction in gingival inflammation and also inflammatory exudate along with formation of new collagen fibers that have been achieved post periodontal flap surgery.

The additional benefit is by the use of collagen is that it is chemotactic for periodontal ligament fibroblasts and improves fibroblast migration and attachment through its scaffold-like fibrillar structure^[76].

The results were in accordance with the studies conducted by Lars Laurell et al (1998), Mark A Reynolds et al (2003)^[92,93] Mary.E.Aichelmann-Reidy, Carlette.D.Heath (2004)^[94,95] in which a significant gain in the relative attachment level was reported from baseline to 6months , 9months and 1 year respectively. They showed an attachment gain of approximately 7.02 ± 0.89 which was comparable to our study.

Gerald M Bowers et al conducted a study to evaluate the potential for regeneration of a new attachment in patients whose attachment apparatus has been destroyed by periodontal disease. Results in 24 defects indicated that new attachment is possible on pathologically exposed roots surfaces in a submerged environment with the incorporation of DFDBA.

Studies carried out by Sugandha Gupta (2016), Sandhu GK et al (2015), Kalra SH et al(2015)^[73,76,80] where 0.8% Gengigel was used for treatment of Grade II furcation defects showed relative attachment gain of 7.00 ± 0.89 at the end of 6months , 7.35 ± 0.92 at 9months and 6.99 ± 0.87 at the end of 1 year respectively.

Horizontal furcation involvement was measured with the help of pre-fabricated stent clinically. To affirm the clinical findings, the radiographic analysis was also done using RVG.

The mean difference in the horizontal furcation involvement in both the groups at the end of 6 months was statistically significant, Group A 2.40 ± 0.52 and 2.80 ± 0.58 in Group B (mean difference from baseline to 6 months) (Table 6.1, table 6.2, Graph 7,8)

This may be due to the fact that DFDBA contains Osteogenin, a bone inductive protein which helped in the regeneration of intrabony defects^[86]. It is believed that BMPs and other noncollagenous proteins in the exposed matrix are responsible for the osteoinductivity of DFDBA^[73].

J.T. Mellonig G.M. (1991)^[39] et al have found improved clinical results after reentry at six months with the use of DFDBA/GTR and greater amount of bone repair with the combination technique.

Similarly in a study done by Sandeep et al (2009)^[96] had done a combination therapy (DFDBA+GTR) was carried out on grade II mandibular furcation defects which showed a mean difference in horizontal furcation of 4.15 ± 0.65 post operatively at 6 months in experimental sites as compared to 3.46 ± 0.56 in controlled sites.

Whereas in the present study Group B (Gengigel®) also showed an improved reduction in horizontal furcation involvement at the end of 6 months.

It is because hyaluronic acid accelerates the bone regeneration by means of chemotaxis, proliferation and successive differentiation of mesenchymal cells.

Hyaluronic acid shares bone induction characteristics with osteogenic substances such as BMP-2 and osteopontin^[85].

Our results tally with the study done by Sugandha Gupta et al., 2017^[83], who used hyaluronic acid (Gengigel[®]) for regeneration in Grade II furcation defects with coronally advanced flap and assessed the sites through surgical re-entry. The authors reported statistically significant mean differences in bone fill in both the horizontal furcation (1.44 ± 0.72) between baseline and 6 months. It was concluded that the additional use of Gengigel[®] leads to better results in hard tissue measurement.

The vertical component of furcation was measured from the floor of the furca to the roof of the furca. The mean defect fill was statistically significant in both the groups at the end of 6 months ($p < 0.05$), Group A 1.45 ± 0.86 and in Group B 1.50 ± 0.58 but there was no improvement seen from the baseline to the end of 1 month (Table 7.1, table 7.2, Graph 9,10)

These findings were in accordance to study done by Mellonig et al (1984)^[39]; in which the defects sites treated with DFDBA showed an average of bone gain 2.6 ± 1.4 mm at the end of 6 months. In this the authors have concluded that demineralization removes the mineral phase of the graft material and purportedly exposes the underlying bone collagen and some growth factors, particularly BMPs which may increase its osteoinductive capabilities.

Another study done by Prathi et al (2008)^[69] showed an average bone fill of about 2.0 ± 1.2 mm at the end of 6 months. DFDBA provides osteoconductive and osteoinductive factors i.e. it induces the host undifferentiated mesenchymal cell to

differentiate into osteoblasts with subsequent formation of new bone. It also contains BMP 2,4 and 7 which help stimulate osteoinduction^[76].

Hyaluronic acid may act as biomaterial scaffold for other molecules, such as BMP-2 and PDGF-BB, used in guided bone regeneration techniques (Hunt DR et al., 2001).

Our results were in accordance to the study done by Kalra S H et al., 2015^[83], used hyaluronic acid (Gengigel[®]) for regeneration in Grade II furcation defects and assessed the sites through surgical re-entry. The authors reported statistically significant mean differences the mean difference in vertical furcation involvement in Group A from baseline to 6months was 1.45 ± 0.86 statistically significant ($p<0.05$).

Sandhu GK et al 2015^[85], reported that the surgical re-entry at 6 months revealed a significant percentage of bone formation in furcation area radiographically and stated a significant improvement in defect fill.

There was no statistical difference that has been observed on intergroup comparison between DFDBA and Gengigel in terms of Sulcus Bleeding Index, Probing Pocket Depth and Relative Attachment Level.

On comparison between the percentage of bone fill between the two groups DFDBA has shown 1% higher percentage of bone fill to that of Gengigel but this value is not statistically significant.

Therefore, within the limitations of our study, it can be concluded that use of DFDBA and 0.8% Gengigel along with a guided tissue regenerative membrane had a beneficial effect in terms of Sulcus Bleeding Index , Probing Pocket Depth , Relative Attachment Level ,Horizontal Furcation Involvement and Vertical Furcation Involvement in both the groups. However, a larger sample size and a long term follow up are necessary to substantiate the results of the study. Also, further research should

be directed in order to evaluate the histological aspect of bone healing during regeneration.

SUMMARY AND CONCLUSION

The present study was a randomized controlled clinical trial that aimed to compare and evaluate the use of Demineralized Freeze Dried Bone Allograft(DFDBA) and Gengigel[®] (0.8%) along with a Guided Tissue Regenerative Membrane(GTR) for the treatment of Grade II furcation defects.

A total of 13 patients presenting with bilateral mandibular Grade II furcation defects , reporting to the out-patient Department of Periodontics, KAHER's KLE V.K. Institute of Dental Sciences, Belagavi were included in the study.

An informed consent was taken from all the included patients. They were randomly divided into two groups by lottery method of randomization into Group A in which defects were treated with DFDBA+ GTR and Group B with Gengigel[®]+GTR. The patients were clinically and radiographically evaluated at baseline, 1 month and 6 months.

The parameters, Sulcus Bleeding Index (SBI), Probing Pocket Depth (PPD), Relative Attachment Level (RAL), Horizontal Furcation Involvement (HFI) and Vertical Furcation Involvement (VFI) were assessed at baseline, 1 month and 6 months. Out of 13 patients, 3 patients couldn't report for follow-up. Hence statistical analysis was carried out for 10 patients.

Both groups showed significant improvement in all parameters. A statistically significant improvement in Sulcus Bleeding Index , Probing Pocket Depth, Relative Attachment Level, Horizontal Furcation Involvement and Vertical Furcation Involvement was seen in both the groups at the end of 6 months follow-up period .

The most desirable outcome of regenerative therapy is the closure of the furcation defects. The following conclusions were drawn from the study.

1. There was statistically significant reduction in Sulcus Bleeding Index, pocket probing depth , relative attachment level, horizontal furcation involvement in both the groups. On comparison there was statistically no significant difference between the two groups.
2. There was statistically no significant change observed in relation to percentage of bone fill at the end of 1 month. But Group A (DFDBA+GTR) showed 0.25 ± 0.10 mm amount of bone fill more compared to that of Gengigel[®] at the end of 6 months. But the result is not statistically significant.

Since, hyaluronic acid shares bone induction characteristics with osteogenic substances such as BMP-2 and osteopontin it enhanced the outcome of the procedure . No histological evaluation was done in our study; hence the overall effect of Gengigel[®] on regeneration capacity remains undetermined.

Within the limitations of our study, it can be concluded that use of DFDBA and 0.8% Gengigel along with a guided tissue regenerative membrane had an additive effect in terms of both clinical and radiographic parameters.

However, controlled clinical trials are required with larger sample size and long-term follow-up to validate the regenerative capabilities of these materials where, histologic evaluation and surgical re-entry would be more appropriate methods to confirm the findings.

BIBLIOGRAPHY

1. Newman MG, Takei HH, Klokkevold PR, Carranza FA. *Clinical Periodontology*, Saunders, Elsevier, St. Louis, Missouri, 10th Edition.
2. Lin N-H, Gronthos S, Bartold PM. Stem cells and periodontal regeneration. *Aust Dent J* 2008; 53:108-121.
3. Walter C, Weiger R, Zitzmann NU. Periodontal surgery in furcation-involved maxillary molars revisited - an introduction of guidelines for comprehensive treatment. *Clin Oral Invest*. 2011; 15:9-20.
4. Mendes RM, Silva GA, Lima MF, Calliari MV, Almeida AP, Alves JB, et al. Sodium hyaluronate accelerates the healing process in tooth sockets of rats. *Arch Oral Biol* 2008; 53:1155-62.
5. Mahgoub MA, Ammar A, Fayez M, Edris A, Hazem A, Akl M, et al. Neovascularization of the amniotic membrane as a biological immune barrier. *Transplant Proc* 2004; 36:1194-8.
6. Holtzclaw DJ and Toscano NJ. Amnion-chorion allograft barrier used for guided tissue regeneration treatment of periodontal intrabony defects: a retrospective observational report. *Clinical Advances in Periodontics*, 2013; Vol. 3, no. 3, pp. 131–137.
7. American Academy of Periodontology. *Glossary of Periodontal Terms*, 4th ed. Chicago: American Academy of Periodontology; 2001.
8. Santos KM, Pinto SC, Pochapski MT, Wambier DS, Pilatti GL, Santos FA. Molar furcation entrance and its relation to the width of curette blades used in periodontal mechanical therapy. *Int J Dent Hyg*. 2009;7(4):263–269.

9. Pepelassi EM, Bissada NF, Greenwell H, Farah CF. Doxycyclinetricalciumphosphate composite graft facilitates osseous healing in advanced periodontalfurcation defects. *J Periodontol*. 1991;62(2):106–115.
10. Hirschfeld L, Wasserman B. A long-term survey of tooth loss in 600 treatedperiodontal patients. *J Periodontol* 1978;49:225-237.
11. Nordland P, Garrett S, Kiger R, Vanooteghem R, Hutchens LH, Egelberg J. The effect of plaque control and root debridement in molar teeth. *J ClinPeriodontol* 1987;14:231-236.
12. Claffey N, Egelberg J. Clinical characteristics of periodontal sites with probing attachment loss following initial periodontal treatment. *J ClinPeriodontol* 1994; 21:670-679.
13. Chowdhary Z, Mohan R. Furcation involvement: Still a dilemma. *Indian JMultidiscip Dent* 2017;7:34-40
14. Glickman I. *Clinical Periodontology*. Philadelphia: W.B. Saunders; 1958.
15. Goldman HM. Therapy of the incipient bifurcation involvement. *J Periodontol*1958;29:112.
16. Staffileno HJ. Surgical management of the furca invasion. *Dent Clin NorthAm* 1969;13:103-119.
17. Easley JR, Drennan GA. Morphological classification of the furca. *J Can DentAssoc (Tor)* 1969;35:104-107.
18. Hamp SE, Nyman S, Lindhe J. Periodontal treatment of multirooted teeth. Results after 5 years. *J Clin Periodontol* 1975;2:126-135.
19. Ramfjord S. *Periodontology and Periodontics*. Philadelphia: W.B. Saunders;1979.

20. Tarnow D, Fletcher P. Classification of the vertical component of furcationinvolvement. *J Periodontol* 1984;55:283-284
21. Hou GL, Chen YM, Tsai CC, Weisgold AS. A new classification of molarfurcation involvement based on the root trunk and horizontal and vertical bone loss. *Int J Periodontics Restorative Dent* 1998; 18:257-265.
22. Gustavo Avila-Ortiz, Juan G. De Buitrago, Michael S. Reddy. Periodontal Regeneration – Furcation Defects: A Systematic Review From the AAP Regeneration Workshop. *J Periodontol* 2015; 86: S108-S130.
23. Greenstein G, Caton JG. Biodegradable barriers and guided tissue regeneration. *Periodontol 2000* 1993;1:36-45.
24. Songa Vajra Madhuri. Membranes for Periodontal Regeneration. *International Journal of Pharmaceutical Science Invention* 2016; 5(6):19-24
25. Ira Gupta, Rohit Gupta, Shankar T Gokhale, and Anjali Sharma. Placental tissues: fixing smile. *International Journal of Innovation and Scientific Research*. 2014; 7(1):57-62.
26. Koizumi NJ, Inatomi TJ, Sotozono CJ, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. *Curr Eye Res* 2000; 20:173-7.
27. Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater* 2008; 15:88-99.
28. Suresh DK, Gupta A. Gingival biotype enhancement and root coverage using human placental chorion membrane. *Clin Adv Periodontics* 2013; 3:237-242.

29. Bourne G. The foetal membranes. A review of the anatomy of normal amnion and chorion and some aspects of their function. *Postgrad Med J* 1962;38:193-201.
30. Steinberg AD, LeBreton G, Willey R, Mukherjee S, Lipowski J. Extravascular clot formation and platelet activation on variously treated root surfaces. *J Periodontol* 1986; 57:516-522.
31. Ruoslahti RE. Fibronectin. *J Oral Pathol* 1981;10:3-13.
32. Baum BJ, Wright WE. Demonstration of fibronectin as a major extracellular protein of human gingival fibroblasts. *J Dent Res* 1980; 59:631-637.
33. Holtzclaw D, Toscano N. Amnion chorion allograft barrier: Indications and techniques update. *J Implant Adv Clin Dent* 2012;4(2):25-38.
34. Holtzclaw D, Hinze HF, Toscano N. Gingival flap attachment healing with amnion-chorion allograft membrane: A controlled, split mouth case report replication of the classic 1968 Hiatt Study. *J Implant Adv Clin Dent* 2012;4(5):19-25.
35. J.W. Streilein, "Unraveling immune privilege," *Science*, vol. 270, no. 5239, pp. 1158–1159, 1995.
36. C. F. Whitsett, J. H. Priest, R. E. Priest, and J. Marion, "HLA typing of cultured amniotic fluid cells," *American Journal of Clinical Pathology*, vol. 79, no. 2, pp. 186–194, 1983.
37. M. F. Gomes, M. J. D. dos Anjos, T. D. Nogueira, and S. A. C. Guimarães, "Histologic evaluation of the osteoinductive property of autogenous demineralized dentin matrix on surgical bone defects in rabbit skulls using human amniotic membrane for guided bone regeneration,"

- International Journal of Oral and Maxillofacial Implants, vol. 16, no. 4, pp. 563–571, 2001.
38. M. Rinastiti, Harijadi, A. L. S. Santoso, and W. Sosroseno, “Histologicalevaluation of rabbit gingival wound healing transplantedwith humanamnioticmembrane,” International Journal of Oral and Maxillofacial Surgery, vol. 35, no. 3, pp. 247–251, 2006.
39. M. D. G. Vilela-Goulart, R. T. S. Teixeira, D. C. Rangel, W. Niccoli-Filho, and M. F. Gomes, “Homogenous amnioticmembrane as a biological dressingfor oral mucositis in rats: histomorphometric analysis,” Archives of OralBiology, vol. 53, no. 12, pp. 1163–1171, 2008.
40. R. Guler, M. T. Ercan, N. Ulutunc, el, H. Devrim, and N. Uran, “Measurementof blood flow by the ¹³³Xe clearance technique to grafts of amnion used investibuloplasty,” British Journal of Oral andMaxillofacial Surgery, vol. 35, no.4, pp. 280–283, 1997.
41. S.Basa, M. T. Ercan, T. Aras, andK. Araz, “Blood flow to palatal mucosalgrafts in mandibular labial vestibuloplasty measured by ¹³³Xe clearancetechnique,” International Journal of Oral and Maxillofacial Surgery, vol. 16, no. 5, pp. 548–553, 1987.
42. M. H. Samandari, M. Yaghmaei, M. Ejlali, M. Moshref, and A.S. Saffar, “Useof amnion as a graft material in vestibuloplasty: a preliminary report,” OralSurgery, OralMedicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 97, no. 5, pp. 574–578, 2004.
43. B.Gurinsky, “A novel dehydrated amnion allograft for use in the treatment ofgingival recession: an observational case series,” The Journal of Implant&Advanced Clinical Dentistry, vol. 1, pp.65–73, 2009.

44. S. V. Kothiwale, P. Anuroopa, and A. L. Gajiwala, "A clinical and radiological evaluation of DFDBA with amniotic membrane versus bovine-derived xenograft with amniotic membrane in human periodontal grade II furcation defects," *Cell and Tissue Banking*, vol. 10, no. 4, pp. 317–326, 2009.
45. S. Wallace, "Radiographic and histomorphometric analysis of amniotic allograft tissue in ridge preservation: a case report," *The Journal of Implant & Advanced Clinical Dentistry*, vol. 2, pp. 49–55, 2010.
46. N. Arai, H. Tsuno, M. Okabe et al., "Clinical application of a hyperdry amniotic membrane on surgical defects of the oral mucosa," *Journal of Oral and Maxillofacial Surgery*, vol. 70, no. 9, pp. 2221–2228, 2012.
47. P. S. Rosen, "Comprehensive periodontal regenerative care: combination therapy involving bone allograft, a biologic, a barrier, and a subepithelial connective tissue graft to correct hard and soft-tissue deformities," *Clinical Advances in Periodontics*, vol. 1, no. 2, pp. 154–159, 2011.
48. A. Chopra and B. S. Thomas, "Amniotic membrane: a novel material for regeneration and repair," *Journal of Biomimetics, Biomaterials and Tissue Engineering*, vol. 18, article 106, 2013.
49. Chen E, Tofe A. A literature review of the safety and biocompatibility of amnion tissue. *J Implant Adv Clin Dent* 2009;2:67-75.
50. Kothiwale SV. The evaluation of chorionic membrane in guided tissue regeneration for periodontal pocket therapy: A clinical and radiographic study. *Cell Tissue Bank*. 2014;15:145–52.

51. S. S. Shetty, A. Chatterjee, and S. Bose, "Bilateral multiple recession coverage with platelet-rich fibrin in comparison with amniotic membrane," *Journal of Indian Society of Periodontology*, vol. 18, no. 1, pp. 102–106, 2014.
52. Esteves J, Bhat KM, Thomas B, Jothi MV, Jadhav T. Efficacy of Human Chorion Membrane Allograft for Recession Coverage- A Case Series 2015, Vol. 86, No. 8, Pages 941-944
53. Shah R, Thomas R, Mehta DS. Ridge preservation using demineralized freeze dried bone allograft and chorion membrane. *Int J Oral Health Sci* 2014; 4:89-
54. Sonali Chakraborty, Savita Sambashivaiah, Rithesh Kulal, Shivaprasad Bilchodmath. Amnion and Chorion Allografts in Combination with Coronally Advanced Flap in the Treatment of Gingival Recession: A Clinical Study. *Journal of Clinical and Diagnostic Research*. 2015 Sep, Vol-9(9): ZC98-ZC101.
55. Mahajan R, Khinda PK, Shewale A, Saravanan SP. Guided Tissue Regeneration Based Treatment of Root Coverage using Placental Membrane Allograft: A Case Report. *IJSS Case Reports & Reviews* 2015; 2(7):1-5.
56. Kothiwale, S., Rathore, A. & Panjwani, V. *Cell Tissue Bank* (2016) 17: 33.
57. Vedamurthy M. Soft tissue augmentation - Use of hyaluronic acid as dermal filler. *Indian J Dermatol Venereol Leprol* 2004;70:383-7.
58. Rahemtulla F. Proteoglycans of oral tissues. *Crit Rev Oral Biol Med* 1992;3:3-67.
59. Pagnacco A, Vangelisti R, Erra C, Poma A. Double-blind clinical trial versus placebo of a new sodium-hyaluronate-based gingival gel. *Attual Ter In*. 1997;15:1–7.

60. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet*.2005; 366:1809–20.
61. Sardi Jde C. Oxidative stress in diabetes and periodontitis. *N Am J Med Sci*.2013;5:58–9.
62. Pendyala G, Thomas B, Joshi SR. Evaluation of total antioxidant capacity ofsaliva in type 2 diabetic patients with and without periodontal disease: A casecontrolstudy. *N Am J Med Sci*. 2013;5:51–75.
63. Moseley R, Waddington RJ, Embery G. Hyaluronan and its potential role inperiodontal healing. *Dent Update*. 2002;29:144–8.
64. Sutherland IW. Novel and established applications of microbialpolysaccharides. *Trends Biotechnol* 1998; 16:41-6.
65. Weigel PH, Frost SJ, McGary CT, LeBoeuf RD. The role of hyaluronic acid ininflammation and wound healing. *Int J Tissue React* 1988; 10:355-65.
66. Toole BP. Hyaluronan in morphogenesis. *Semin Cell Dev Biol* 2001;12:79-87
67. Deed R, Rooney P, Kumar P, Norton JD, Smith J, Freemont AJ, et al. Earlyresponse gene signalling is induced by angiogenic oligosaccharides ofhyaluronan in endothelial cells. Inhibition by non-angiogenic, high molecularweighthyaluronan. *Int J Cancer* 1997; 71:251-6.
68. Mendes RM, Silva GA, Lima MF, Calliari MV, Almeida AP, Alves JB, et al.Sodium hyaluronate accelerates the healing process in tooth sockets of rats.*Arch Oral Biol* 2008; 53:1155-62. Hunt DR, Jovanovic SA, Wikesjö UM,Wozney JM, Bernard GW.
69. Hunt DR, Jovanovic SA, Wikesjö UM, Wozney JM, Bernard GW.Hyaluronansupports recombinant human bone morphogenetic protein-2

- induced bonereconstruction of advanced alveolar ridge defects in dogs. A pilot study. *JPeriodontol* 2001;72:651-8.
70. Pirnazar P, Wolinsky L, Nachnani S, Haake S, Pilloni A, Bernard GW. Bacteriostatic effects of hyaluronic acid. *J Periodontol* 1999;70:370-4.
71. Bansal J, Kedige SD, Anand S. Hyaluronic acid: A promising mediator for periodontal regeneration. *Indian J Dent Res* 2010;21:575-8.
72. Sasaki T, Kawamata-Kido H. Providing an environment for reparative dentine induction in amputated rat molar pulp by high molecular-weight hyaluronic acid. *Archs Oral Biol.* 1995; 40:209-19.
73. Hunt DR, Jovanovic SA, Wikerjo UME, Wozney JM, Bernard GW. Hyaluronan supports recombinant human bone morphogenetic protein-2 induced bone reconstruction of advanced alveolar ridge defects in dogs. A pilot study. *J Periodontol.* 2001;72:651-58.
74. Pistorius A, Martin M, Willershausen B, Rockmann P. The clinical application of hyaluronic acid in gingivitis therapy. *Quintessence Int.* 2005;36:531-8.
75. Koshal A, Patel P, Robert B, Galgut Peter N. A comparison in postoperative healing of sites receiving non-surgical debridement augmented with and without a single application of hyaluronan 0.8% gel. *Prev Dent* 2007;2:34-8.
76. de Araújo Nobre M, Cintra N, Maló P. Peri-implant maintenance of immediate function implants: A pilot study comparing hyaluronic acid and chlorhexidine. *Int J Dent Hyg.* 2007;5:87-94.



77. Ballini A, Cantore S, Capodiferro S, Grassi FR. Esterified Hyaluronic acid and autologous bone in the surgical correction of the infra-bone defects. *Int J MedSci*. 2009;6(2):65-71.
78. Vanden Bogaerde L. Treatment of infrabony periodontal defects with esterified hyaluronic acid: Clinical report of 19 consecutive lesions. *Int J Periodontics Restorative Dent*. 2009;29:315–23.
79. Nadiger S and Kharidi VL. Evaluation of hyaluronan gel (Gengigel®) as atopic applicant in the treatment of gingivitis. *Journal of investigative and clinical dentistry*. 2011; 2(3): 162-170.
80. Pilloni A, Annibali S, Dominici F, Di Paolo C, Papa M, Cassini MA, et al. Evaluation of the efficacy of an hyaluronic acid-based biogel on periodontal clinical parameters. A randomized-controlled clinical pilot study. *Ann Stomatol (Roma)* 2011;2:3–9.
81. Gontiya G, Galgali S. Effect of hyaluronan on periodontitis: Clinical and histological study. *J Indian Soc of Periodontol*. 2012;16(2):184-92.
82. Fawzy El-Sayed KM, Dahaba MA, Aboul-Ela S, Darhous MS. Local application of hyaluronan gel in conjunction with periodontal surgery: A randomized controlled trial. *Clin Oral Investig* 2012;16:1229-36.
83. Sahayata Vishal N, Bhavsar Neeta V, Brahmabhatt Nilam A. An Evaluation of 0.2% Hyaluronic Acid Gel (Gengigel®) in the Treatment of Gingivitis: A Clinical & Microbiological Study. *OHDM - Vol. 13 - No. 3 - September, 2014*.
84. Radhika Kumar, Moogala Srinivas, Jagdish Pai, Girish Suragimath, Krishna Prasad, Tejaswin Polepalle. *Journal of Indian Society of Periodontology – Vol 18, Issue 6, Nov-Dec 2014*.

85. Sandhu GK, Khinda PK, Gill AS, Kalra HS. Surgical re-entry evaluation of regenerative efficacy of bioactive Gengigel® and platelet-rich fibrin in the treatment of grade II furcation: A novel approach. *Contemp Clin Dent*. 2015;6(4):570-73.
86. Kalra SH, Monga C, Kalra KH, Kalra SH. A roentgenographic assessment of regenerative efficacy of bioactive Gengigel® in conjunction with amnion membrane in grade II furcation defect. *Contemp Clin Dent*. 2015;6(2):277-80.
87. Batavia PD, Bhushan KS, Vandana KL, Desai R. Use of hyaluronan (Gengigel) in the treatment of gingivitis in orthodontic patients: A clinical, biochemical, and microbiological study. *J Int Clin Dent Res Organ* 2016;8:44-50.
88. Sugandha Gupta, Suresh D Kediege, Akanksha Gupta, Kanu Jain. Evaluation of Gengigel® Application in the Management of Furcation with Coronally Advanced Flap through Surgical Re-Entry- A Split Mouth Clinical Study *Journal of Clinical and Diagnostic Research*. 2017 Jan, Vol-11(1): ZC27-ZC32.
89. Carranza FA, Newman MG. *Clinical Periodontology*, WB Saunders & Co., Philadelphia, 8th Edition, Page 61-82.
90. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. *Int Dent J*. 1975 Dec; 25(4):229-35.
91. Bjorn H, Halling A, Thyberg H. Radiographic assessment of marginal bone loss. *Odontologisk Revy* (1969) 20: 165-179.
92. Schei O, Waerhaug J, Lovdal A, Arno A. Alveolar bone loss as related to oral hygiene and age. *Journal of Periodontology* 1959;30:7-16.

93. Linares A, Cortellini P, Lang NP, Suvan J, Tonetti MS on behalf of the European Research Group on Periodontology (ErgoPerio) Guided Tissue Regeneration/ deproteinized bovine bone mineral or papilla preservation flap alone for treatment of intrabony defects II: Radiographic predictors and outcomes. *J Clin Periodontol* 2006;33:351-8.
94. Hakansson L, Hällgren R, Venge P. Regulation of granulocyte function by hyaluronic acid. In vitro and in vivo effects on phagocytosis, locomotion, and metabolism. *J Clin Invest.* 1980;66:298–305.
95. Pakkala T, Virtanen I, Oksanen J, Jones C, Hormia M (2002) Function of laminins and laminin-binding integrins in gingival epithelial cell adhesion. *J Periodontol* 73(7):709–719.
96. Hao Y, Ma D, Hwang D, Kim W, Zhang F (2000) Identification of antiangiogenic and anti-inflammatory proteins in human amniotic membrane. *Cornea* 19(3):348–352.

ANNEXURE-I

ETHICAL CLEARANCE

	<p>Research and Ethics Committee KLE V K INSTITUTE OF DENTAL SCIENCES KLE University</p> <p>Accredited 'A' Grade by NAAC Placed in Category 'A' by MHRD (Govt) Nehru Nagar, Belagavi - 590 010, Karnataka State</p> <p>☎: 0831-2470362 Web: http://www.kledental-bgm.edu.in FAX: 0831-2470640 E-mail: principal@kledental-bgm.edu.in</p>	
		Sl. No. : 1224
CERTIFICATE		
<p><i>This is to Certify that the synopsis titled</i></p> <p><i>Comparative evaluation of demineralized freeze dried bone allograft (DFDBA) and gengigel along with a guided tissue membrane for the treatment of grade II furcation defects: A randomised controlled clinical trial</i> Submitted by</p> <p><i>Dr. Rohita Pendyala</i> P. G. Student /</p> <p><i>Staff, Guided by Dr. Abhishek Zingade</i> from Department of</p> <p><i>Periodontics</i> has been critically evaluated by</p> <p><i>committee members and granted ethical clearance to conduct the above mentioned study</i></p>		
<p>Date : 24/06/2019</p>		
<p>Member Secretary Research and Ethical Committee KLEVK Institute of Dental Sciences Belagavi</p>		<p>Chairman Research and Ethical Committee KLEVK Institute of Dental Sciences Belagavi</p>

ANNEXURE-II

DEPARTMENT OF PERIODONTICS

KLE VK INSTITUTE OF DENTAL SCIENCES, BELAGAVI

CONSENT FORM

**A CLINICAL AND RADIOGRAPHIC ASSESSMENT OF DEMINERALIZED
FREEZE DRIED BONE ALLOGRAFT(DFDBA) AND DFDBA WITH
GENGIGEL IN TREATMENT OF GRADE II FURCATION DEFECTS: A
SPLIT MOUTH COMPARITIVE STUDY**

PRINCIPAL INVESTIGATOR: DR. ROHITA PENDYALA.

I _____, aged _____ years have been informed about my involvement in the study.

I agree to give my personal details like Name, Age, Gender, Residential Address, past and Present dental history and any other details if required for the study to the best of my knowledge.

I will co-operate with the dentist.

I will follow the instructions given by the dentist during study.

I will visit the dentist as and when required for the study, at the given time and date.

I permit the dentist to utilize the information given and results obtained from this study for presentation and publication without disclosing my identity.

I have understood the nature of the study and permit the dentist to carry out the required surgical procedure.

If for any reason I am unable to participate in the study, for reasons unknown, I can withdraw from the study at any given point of time.

I have been informed that the surgical procedure being performed on me for the purpose of bony defect using gengigel is a relatively newer material and after understanding the procedure, I permit the dentist to perform the same.

If by chance any complications arise during the above said procedure, I permit the dentist to take necessary actions to prevent the same.

In my full consciousness and presence of mind, after understanding all the procedures and related complications if any, in my vernacular language, I am willing and give my consent to participate in this study.

Date:

Name of the Patient:

Signature:

Address & Ph. No:

Name of witness/guardian:

Signature:

PRINCIPAL INVESTIGATOR

GUIDE

(Dr.ROHITA PENDYALA) (Dr. ABHISHEKZINGADE)

CONSENT FORM
DEPARTMENT OF PERIODONTICS
KLE V.K.INSTITUTE OF DENTAL SCIENCES
BELAGAVI.

**COMPARITIVE EVALUATION OF DEMINERALIZED FREEZE
DRIED BONE ALLOGRAFT (DFDBA) AND GENGIGEL ALONG
WITH A GUIDED TISSUE REGENERATION MEMBRANE FOR
THE TREATMENT OF GRADE II FURCATION DEFECTS:A
RANDOMIZED CONTROL CLINICAL TRAIL.**

Principal Investigator :Dr.RohitaPendyala

ನಾನು _____, ವಯಸ್ಸಿನ _____
ವರ್ಷಗಳ ಅಧ್ಯಯನದಲ್ಲಿ ನನ್ನ ತೂಡಗರುವ ಬಗ್ಗೆ ತಿಳಿಸಲಾಗಿದೆ. ನನ್ನ ಜ್ಞಾನದ ಅತ್ಯುತ್ತಮ ಅಧ್ಯಯನಕ್ಕೆ ಅಗತ್ಯವಿದ್ದರೆ ನನ್ನ ವೈಯಕ್ತಿಕ ವಿವರಗಳನ್ನು ಹೆಸರು, ವಯಸ್ಸು, ಲಿಂಗ, ವಸತಿ ವಿಳಾಸ:

ಹಿಂದಿನ ಮತ್ತು ಪ್ರಸ್ತುತ ದಂತ ಇತಿಹಾಸ ಮತ್ತು ಇತರ ವಿವರಗಳನ್ನು ನೀಡಲು ಒಪ್ಪುತ್ತೇನೆ.

ನಾನು ದಂತವೈದ್ಯರೊಂದಿಗೆ ಸಹಕರಿಸುತ್ತೇನೆ. ಅಧ್ಯಯನದಲ್ಲಿ ದಂತವೈದ್ಯನಿಡಿದ ಸೂಚನೆಗಳನ್ನು ನಾನು ಅನುಸರಿಸುತ್ತೇನೆ. ನಾನು ನಿರ್ದಿಷ್ಟ ಸಮಯದಲ್ಲಿ ಮತ್ತು ದಿನಾಂಕದಂದು ದಂತವೈದ್ಯರಿಗೆ ಮತ್ತು ಅಧ್ಯಯನಕ್ಕೆ ಅಗತ್ಯವಿದ್ದಾಗ ನಾನು ಭೇಟಿ ನೀಡುತ್ತೇನೆ. ನನ್ನ ಗುರುತನ್ನು ಬಹಿರಂಗಪಡಿಸದೆ ಪ್ರಸ್ತುತಿ ಮತ್ತು ಪ್ರಕಟಣೆಗಾಗಿ ಈ ಅಧ್ಯಯನದಿಂದ ಪಡೆದ ಮಾಹಿತಿ ಮತ್ತು ಫಲಿತಾಂಶಗಳನ್ನು ಬಳಸಿಕೊಳ್ಳಲು ನಾನು ದಂತವೈದ್ಯರಿಗೆ ಅನುಮತಿಸುತ್ತೇನೆ.

ನಾನು ಅಧ್ಯಯನದ ಸ್ವಭಾವವನ್ನು ಅರ್ಥಮಾಡಿಕೊಂಡಿದ್ದೇನೆ ಮತ್ತು ತಿಳಿಗತೈಶ್ಚಿಕತೆಗಾಗಿ

ಯಾವುದೇ ವಿಧಾನವನ್ನು ಕೈಗೊಳ್ಳಲು ದಂತವೈದ್ಯರನ್ನು ಅನುಮತಿಸುತ್ತೇನೆ.

ಯಾವುದೇ ಕಾರಣಕ್ಕಾಗಿಯೂ ನಾನು ಅಧ್ಯಯನದಲ್ಲಿ ಪಾಲ್ಗೊಳ್ಳಲು ಸಾಧ್ಯವಾಗದಿದ್ದರೆ,

ಕಾರಣಗಳು ಅಜ್ಞಾತವಾಗಿದ್ದಲ್ಲಿ,

ಯಾವುದೇ ಸಮಯದಲ್ಲಿ ದಂತವೈದ್ಯನಿಂದ ನಾನು ಹಂತಗದುಕೊಳ್ಳಬಹುದು.

Gengigel ಅನ್ನು ಬಳಸಿಕೊಂಡು ಮೂಲದೋಷದ ಉದ್ದೇಶಕ್ಕಾಗಿ ನನ್ನ ಮೇಲೆ ನಡೆಸಿದ ಶಸ್ತ್ರ

ಚಿಕಿತ್ಸಾ ಪ್ರಕ್ರಿಯೆಯು ತುಲನಾತ್ಮಕವಾಗಿ ಹೊಸವಸ್ತುವಾಗಿದೆ ಮತ್ತು ಕಾರ್ಯವಿಧಾನವನ್ನು ಅ

ರ್ಥಮಾಡಿಕೊಂಡ ನಂತರ ನಾನು ದಂತವೈದ್ಯರನ್ನು ಅದೇ ರೀತಿಯಲ್ಲಿ ಮಾಹಿತಿ ನೀಡಲು ಅನುಮತಿಸುತ್ತೇನೆ.

ಎಂದನನಗತಳಿಸಲಾಗದ.

ಮೇಲೆ ತಿಳಿಸಿದ ಪ್ರಕ್ರಿಯೆಯಲ್ಲಿ ಯಾವುದೇ ತೊಂದರಗಳು ಉಂಟಾದರೂ,

ದಂತವೈದ್ಯರು ಅದನ್ನು ತಡೆಯಲು ಅಗತ್ಯ ಕ್ರಮಗಳನ್ನು ತೆಗೆದುಕೊಳ್ಳುವಂತೆ ನಾನು ಅನುಮತಿ

ಸುತ್ತೇನೆ.

ನನ್ನ ಸಂಪೂರ್ಣ ಪ್ರಜ್ಞೆ ಮತ್ತು ಮನಸ್ಸಿನ ಉಪಸ್ಥಿತಿಯಲ್ಲಿ,

ಎಲ್ಲ ವಿಧಾನಗಳು ಮತ್ತು ಸಂಬಂಧಿತ ಸಮಸ್ಯೆಗಳನ್ನು ಅರ್ಥಮಾಡಿಕೊಂಡ ನಂತರ,

ನನ್ನ ದೇಶೀಯ ಭಾಷೆಯಲ್ಲಿ,

ನಾನು ಈ ಅಧ್ಯಯನದಲ್ಲಿ ಪಾಲ್ಗೊಳ್ಳಲು ಸನ್ನಿಹಿತವಾಗಿದ್ದು ನನ್ನ ನೋಡುತನ ಮತ್ತು ನನ್ನ ಒಪ್ಪಿಗೆಯ

ನ್ನು ನೀಡುತ್ತೇನೆ.

Date: _____

Name of the Patient: _____

Signature: _____

Address & Ph. No: _____

PRINCIPAL INVESTIGATOR

GUIDE

(Dr. ROHITA PENDYALA) (Dr. ABHISHEK ZINGADE)

Name of witness/guardian: _____

Signature: _____

CONSENT FORM
DEPARTMENT OF PERIODONTICS
KLE V.K.INSTITUTE OF DENTAL SCIENCES
BELAGAVI.

**COMPARITIVE EVALUATION OF DEMINERALIZED FREEZE
DRIED BONE ALLOGRAFT (DFDBA) AND GENGIGEL ALONG
WITH A GUIDED TISSUE REGENERATION MEMBRANE FOR
THE TREATMENT OF GRADE II FURCATION DEFECTS:A
RANDOMIZED CONTROL CLINICAL TRAIL.**

Principal Investigator :Dr.RohitaPendyala

- मी _____, वय _____
वर्षलामाझ्यावरीलसंशोधनातसहभागीहोण्याचीकल्पनादिलेलीआहे.
- मीमाझेवैयक्तिकमाहिती, _____ जसेनाव,वय,लिंग,घरचापत्ता,
पूर्वाणिसध्याचालूअसलेलादंतइतिहासआणिसंशोधनासाठीआवश्यकअ
सलेलीसर्वमाहितीदेऊइच्छीतो/ते.
- मीदंतचिकित्सकांनात्यांच्या अभ्यासात सहकार्यकरीन.
- मीदंतचिकित्सकांनीदिलेल्यासर्वसूचनापाळीन.
- मीदंतचिकित्सकांनीसंशोधनाकरिताजेव्हाबोलावलंतेव्हादिलेल्यादिवशी
आणिवेळेतयेईन.
- मीदंतचिकित्सकांनामीदिलेलीमाहितीआणिसंशोधनातमिळालेलेपरिणाम
माझीओळखउघडनकरताप्रसारणकरण्याचीपरवानगीदेतो/ते .
- मला _____ दंतचिकित्सकांचा
अभ्याससमजलाआहेआणित्यासाठीआवश्यकअसलेलीशस्त्रक्रियाअमलात
आणणेआणित्यासाठीदंतचिकित्सकांनामीपरवानगीआहे.
- कोणत्याहीकरणस्पतीमीसंशोधनातसहभागीहोऊशकलेनाही
(अज्ञातकारणांमुळे), तरमीकोणत्याहीवेळीसंशोधनसोडूशकतो/ते.

- मलासूचितकेलेगेलेआहेकीजिंजिजेल चावापरबोनिडिफेक्ट मध्ये केला जाईल. माझ्यावरवापरलं जाणारं जिंजिजेलहेएकतुलनेनेनवीनसाहित्यआहेआणिप्रक्रियासमजूनघेतल्यानंतर रमीदंतचिकित्सकयांनातसेकरण्याचीपरवानगीदेतो.
- वरील नमुद केलेल्याप्रक्रियेदरम्यानकोणतीहीसमस्याउद्भवलीतरमीदंतचिकित्सकांना झालेली समस्या टाळण्यासआवश्यककार्यवाहीकरण्यासपरवानगीदेतो.
- मीपुर्ण शुद्धीतआणिमनाच्याउपस्थिती, माझ्यामातृभाषेतसर्वप्रक्रियाआणिसंबंधितसमस्यासमजूनघेतल्यानंतर, मीयाअभ्यासातभागघेण्यासाठीमाझीइच्छाव्यक्तकरतो/ते

Date:

Name of the Patient: _____

Signature:

Address & Ph. No:

PRINCIPAL INVESTIGATOR GUIDE
(Dr. ROHITA PENDYALA) (Dr. ABHISHEK ZINGADE)

Name of witness/guardian:

Signature:

ANNEXURE-III

PROFORMA

**KLE V.K.INSTITUTE OF DENTAL SCIENCES
BELAGAVI.**

Comparitive evaluation of demineralized freeze dried bone allograft (DFDBA) and gengigel along with a guided tissue regeneration membrane for the treatment of grade ii furcation defects :A RandomisedControl Clinical Trial.

Case No:

OPD No:

Name:

Age:

Sex:

Occupation:

Address:

Chief Complaint:

Medical history:

Dental history:

Personal habits:

CLINICAL PARAMETERS

SULCUS BLEEDING INDEX:

8	7	6	5	4	3	2	1	1	2	3	4	5	6	7	8	

POCKET PROBING DEPTH:

8	7	6	5	4	3	2	1	1	2	3	4	5	6	7	8	

RELATIVE ATTACHMENT LEVEL:

8	7	6	5	4	3	2	1	1	2	3	4	5	6	7	8	

PARAMETER	BASELINE	1 MONTH	6 MONTHS
EVALUATION OF CLINICAL PARAMETERS			
RELATIVE ATTACHMENT LEVEL			
BLEEDING INDEX			
POCKET PROBING DEPTH			
EVALUATION OF FURCATION INVOLVEMENT			
HORIZONTAL COMPONENT			
VERTICAL COMPONENT			


Amount of bone fill from baseline to 6 months:

Patient Information Sheet

- I Dr.RohitaPendyala, will be conducting the study.
- In this study only the tooth with grade II furcation will be taken.
- Patient will be explained about the procedure and after their willing the study will be conducted.
- In the first appointment clinical parameters will be noted and radiograph of the tooth will be taken . Scaling will be done and after 3 weeks of phase 1 therapy the patient will be recalled. In this appointment impression will be taken .
- In the second appointment, blood investigations will be done prior to the treatment of the defective area of the tooth after which placement of bone graft on one side and gengigel on the other side along with collagen membrane will be done.
- In the third appointment and fourth appointment that is after 1month and 6 month of surgery clinical parameters will be recorded again along with radiographic assessment.
- These measurements(clinical and radiographic) taken will be used for the research study.
- Patient will have to cooperate with the dentist.



Introduction



Aim and Objectives



Review of Literature



Methodology



Results



Discussion



Summary And Conclusion



Bibliography



Annexures
